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ABSTRACT 
 
Needle Exchange Programs to Prevent Hepatitis C Virus Infection in 
People Who Inject Drugs in Rural Appalachia 
 
Stephen M. Davis 
The recent opioid epidemic in the rural Appalachian region of the United States 
has fueled an exponential increase in hepatitis C virus (HCV) infection among People 
Who Inject Drugs (PWID).  Needle exchange programs (NEP), which provide clean 
needles in exchange for used needles, can reduce the incidence of HCV among 
PWIDs.  However, the empirical evidence examining NEP effectiveness in the 
prevention of HCV in this population is mixed, only describes studies conducted in 
urban areas, and does not address the unique challenges associated with implementing 
NEPs in rural areas.  Furthermore, no studies have examined barriers to using clean 
needles obtained from NEPs in rural settings.  Therefore, there is a critical need to 
understand the unique context and programmatic challenges of rural NEPs to design 
and implement successful programs to reduce HCV transmission in this underserved 
population.  The objective of this dissertation was to improve empirical evidence related 
to NEP efficacy, examine programmatic challenges encountered by rural NEPs, and 
identify clean needle use barriers unique to rural areas.  The rationale underlying this 
research is that improved understanding of operational and clean needle use barriers 
will promote successful implementation of NEPs in rural areas.  In the first study, a 
systematic review with meta-analysis was conducted to update the empirical evidence 
related to NEP prevention of HCV in PWIDs.  Findings from this study revealed that the 
overall impact of NEPs on HCV prevention remains unclear and is complicated by 
significant heterogeneity between studies.  Furthermore, no rural studies were identified 
in the review.  Standardization of population characteristics, intervention components, 
empirical comparisons, and outcome assessments is suggested to reduce 
heterogeneity and clarify the empirical contribution of NEPs to HCV prevention.  In the 
second study, a qualitative case study design was employed to examine barriers and 
facilitators to NEP implementation, ongoing operations, and future sustainability. 
Structured interviews with program directors, law enforcement leaders and personnel, 
and NEP attendees revealed common barriers and facilitators to program 
operations.  Findings from this study indicated that despite broad community support, 
growing volumes, funding shortages, and the federal government’s prohibition on the 
use of funds to purchase needles threatened program operations.  Furthermore, 
paraphernalia laws created a legal conundrum in the form of criminal sanctions for the 
possession of needles, which may inadvertently promote needle sharing and disease 
transmission.  In the third study, a mixed methods survey of PWIDs attending two rural, 
Appalachian programs regarding barriers to using clean needles obtained from the 
exchange for every injection was employed.  Findings from this study revealed that fear 
of arrest and problems with obtaining clean needles from pharmacies were the most 
commonly endorsed barriers to clean needle use.  The results of this dissertation 
suggest that NEPs opened in rural Central Appalachia in response to an opioid and  
heroin epidemic have enjoyed robust community support and are viewed as an 
important infectious diseases prevention mechanism by PWIDs.  However, the overall 
impact of NEPs on preventing HCV in rural PWIDs is unclear and, similar to urban 
areas of the United States, may be blunted by legal structural influences (i.e. 
paraphernalia laws) that impact policing behaviors.  Future studies should explore the 
factors associated with these structural barriers that may prevent the ability of rural 
PWIDs to use a clean needle during every injection, which, in turn, may minimize the 
overall efficacy of these programs on HCV prevention.  Further research is also needed 
on the feasibility of implementing the addition of opiate replacement therapy (i.e., 
methadone, buprenorphine) with NEPs given the strong protective effect on HCV 
seroconversion observed in several European studies implementing this combined 
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1      INTRODUCTION 
1.1 Hepatitis C Virus Infection in the United States  
1.1.1 Morbidity and Mortality 
Hepatitis C virus (HCV) is a blood-borne virus that infects the liver.1  
Approximately 75% of acute HCV infections become chronic.2  Chronic HCV infection 
significantly increases the risk of liver disease, especially cirrhosis and liver cancer.2-6  
Of the approximately 3 million individuals infected with chronic HCV in the United 
States, it is projected that 1.47 million will develop liver cirrhosis, 350,000 will develop 
liver cancer, and almost 900,000 will die from HCV-related complications.2,5  HCV 
infected patients consume a large proportion of healthcare resources in the United 
States.  Between 2001 and 2010, HCV infected individuals accounted for almost 3 
million outpatient, inpatient, and emergency department visits in the United States.6  
Estimated health care costs associated with the treatment and care of chronic HCV was 
$6.5 billion in 2011, and is expected to peak at $9.1 billion in 2024.3  In 2007, mortality 
from HCV infection surpassed human immunodeficiency virus (HIV), and this trend is 
projected to continue.2,4      
1.1.2  Emerging Epidemic  
 
The incidence of HCV in 
the United States declined from 
2000-2003 and plateaued during 
2006-2010 with 800-1000 new 




cases significantly increased (Figure 1).7  Nationally, from 2010-2015 there was a 2.9 
fold increase in the number of reported acute HCV infections.7  
1.1.2.1 The role of injection drug use and needle sharing  
Recent evidence examining the potential contributing factors underlying the HCV 
epidemic point to the prominent role of injection drug use.2,7-12  People who inject drugs 
(PWID) account for 60%-70% of new HCV infections in the United States.2  The 
prevalence of HCV infection in PWIDs ranges between 40% and 90% and has been 
observed to be as high as 98%.13  Many of these PWIDs are white,2,9,11,12 young (< 35 
years of age),2,7-9,11,12 and have a history of prescription drug use and abuse, especially 
prescription opiates.2,10-12  Among PWIDs, HCV is primarily transmitted through shared 
(used) injection syringes.14  A recent meta-analysis found a 94% increased risk of 
acquiring HCV infection among PWIDs who shared syringes (pooled risk ratio (RR) = 
1.94, 95% confidence interval (CI), 1.53, 2.46).14   
1.1.2.2 The role of rural injectors    
Two recent studies suggest HCV infected PWIDs are more likely to reside in non-
urban areas.11,12  Between 2006 and 2012, there was a staggering 364% increase in 
HCV cases observed in young (≤ 30 years of age) PWIDs in Central Appalachia 
(Kentucky, Tennessee, Virginia, and West Virginia).8  A recent heroin epidemic in this 
region is thought to underlie the HCV epidemic.8,15   
1.2 Needle Exchange Programs  
Needle exchange programs (NEP) are one popular harm reduction intervention 
that provide clean needles in exchange for used needles to minimize the reuse of 




1.2.1  Unclear Efficacy 
The evidence for the effectiveness of NEPs in preventing HCV among PWIDs is 
mixed.17  A review of reviews by MacArthur et al.17 concluded that there was sufficient 
evidence to support the effectiveness of NEPs in reducing risky injection behavior (e.g., 
needle sharing), but found insufficient evidence to support or discount the 
effectiveness of NEPs for the prevention of HCV in PWIDs.  A systematic review with 
meta-analysis of several interventions, including NEPs, to prevent HCV infection in 
PWIDs observed an increased risk of HCV seroconversion associated with NEP use 
(RR 1.62, 95% CI, 1.04, 2.52), although substantial between-study heterogeneity was 
observed (Q = 32.3, P < 0.01, I2 = 81%).13  Additionally, this systematic review only 
included studies published through April 2010 when the current HCV epidemic was 
relatively young.  A more recent systematic review of needle/syringe programs for the 
reduction of HCV infection among PWIDs by Abdul-Quader et al.18 found that 6 of the 
15 included studies (40%) reported decreases in HCV infection. NEPs have also been 
shown to effectively reduce the number of injections per syringe.19   
1.2.2  Barriers to Using Clean Needles and NEP Efficacy 
Although the ability to access clean needles is one important step in fighting the 
HCV epidemic, there are potential barriers to practicing risk reduction strategies (e.g., 
not sharing syringes) that may reduce the efficacy of NEPs.  Barriers to using a clean 
needle for every injection can occur at the individual (e.g., being in drug withdraw), 
interpersonal (e.g., peer influences), and societal (e.g., confiscation of needles by 
police) levels of influence.  For example, Phillips et al.19  recruited heroin injectors in 




associated with risk reduction practices.  Being in drug withdrawal and fear of being 
arrested with needles were the two most frequently reported barriers to using new 
(clean) needles in this sample.  Furthermore, secondary analysis of data from a 
randomized controlled trial that was designed to reduce the risk of human 
immunodeficiency virus (HIV) and sexually transmitted infections among female PWID 
sex workers observed that safe injection self-efficacy was negatively affected by police 
syringe confiscation.20  Similarly, Pollini et al.21 conducted a cross-sectional survey of 
PWIDs in Tijuana and Ciudad Juarez, Mexico to elucidate the association between 
syringe possession arrests and syringe sharing.  After adjustment, arrests for 
possessing both clean needles (aOR 2.05, 95% CI, 1.26, 3.35) and used needles (aOR 
2.87, 95% CI, 1.76, 4.69) were independently associated with receptive syringe sharing.  
1.3  Knowledge Gaps and Dissertation Aims 
Although previous studies have demonstrated the important role of NEPs in 
preventing HCV infection among PWIDs, none were conducted in rural areas of the 
United States.  These rural areas, particularly Central Appalachia, are in the midst of a 
heroin epidemic that is directly contributing to the ongoing, costly HCV epidemic.  
However, the most recently available systematic reviews of the evidence do not include 
any studies that were conducted in rural areas of the United States. Therefore, there is 
a critical need to improve this evidence by conducting an updated systematic review of 
the literature with meta-analytic methods.  Additionally, it is necessary to identify 
programmatic challenges to implementing these programs in rural areas by interviewing 
NEP directors and stakeholders.  Furthermore, the presence of NEPs in rural 




Individual, interpersonal, and societal barriers to the use of clean needles may reduce 
the efficacy of NEPs in preventing HCV infection.  However, no studies describing these 
barriers have been conducted in rural areas of the United States. Therefore, there is a 
critical need to understand the unique context and programmatic challenges of rural 
NEPs to design and implement successful programs to reduce HCV transmission in this 
underserved population. This dissertation proposes to address these knowledge gaps 
via the following three studies: 
 Specific Aim #1:  Conduct a systematic literature review with meta- 
analysis on the efficacy of NEPs in preventing HCV infection among 
PWIDs. 
Hypothesis:  NEPs will demonstrate a protective effect on the acquisition 
of HCV infection among PWIDs. 
 Specific Aim #2:  Identify and compare programmatic facilitators, barriers, 
and innovative solutions between two rural NEPs. 
Research Questions:  What are the facilitators and barriers to opening the 
program?  What are the facilitators and barriers encountered during the day-to-
day running of the program?  What are the future plans for the program, and 
what are challenges and barriers related to these future plans?   
 Specific Aim #3:  Identify self-reported barriers to using a clean needle 
among PWIDs attending NEPs in West Virginia. 
Hypothesis:  Fear of arrest and drug withdrawal will be the most frequently 




Successful completion of these aims will result in an updated understanding of 
the efficacy of NEPs for preventing HCV, and provide previously unknown information 
concerning the operation of these programs in rural areas.  This new information may 
inform the design, implementation, and operation of NEPs in other rural areas to 
mitigate the current HCV epidemic in this underserved population.   
2  APPROACH 
 
2.1  Specific Aim #1  
Conduct a systematic literature review with meta-analysis on the efficacy of 
NEPs in preventing HCV infection among PWIDs. 
Hypothesis #1:  NEPs will demonstrate a protective effect on the acquisition of 
HCV infection among PWIDs. 
2.1.1   Study Design   
The conduct and reporting of this systematic review with meta-analysis will follow 
the recommended guidelines from the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) statement.22   This review is registered in the 
PROSPERO trial registry (CRD42016035315). 
2.1.2   Study Eligibility  
The a priori inclusion criteria are as follows: (1) observational studies, (2) PWIDs, 
(3) NEP use, (4) HCV status ascertained by serological testing (saliva or serum), (5) 
studies published in any language after January 1, 1989, and (6) data available or 
calculable for measures of association between participation in a NEP and HCV 




randomized trials), population, intervention (i.e., supervised injection facility, pharmacy-
based NEP), or lack of available information to calculate a measure of association 
between program participation and HCV infection.  
2.1.3   Data Sources   
The following databases will be searched: (1) PubMed, (2) Scopus, (3) Web of 
Science, and (4) CINAHL. Based on the recommendations of van Driel et al.,23 and 
current practice,23,24 no searches for unpublished works or reports will be conducted. 
The search strategy and terms were based on the work of the HCV synthesis project,25 
and Abdul-Quader et al.18  The term “people who inject drugs” was included in the 
search since it is now commonly used to refer to injection drug users (Figure 2).  Cross-
referencing from retrieved studies and reviews will also be conducted.  The number 
needed to read (NNR) will be calculated by taking the inverse of the precision, which is 
defined as the number of included studies divided by the total number of  
studies screened after removal of 
duplicates.26  All studies identified 
during the search will be stored in 
Endnote® version 7.4.27  
2.1.4   Study Selection  
  Two researchers will 
independently review, select, and 
abstract data from eligible studies with discrepancies resolved by a third researcher, if 
needed.  The risk of bias in selected studies will be assessed using the Newcastle-
Figure 2.  Example Search String 
(hepatitis C OR HCV) AND (intravenous drug abuse OR intravenous 
drug use OR drug misuse OR drug addict OR injecting drug use OR 
drug abuse OR people who inject drugs OR PWID OR PWID) AND 
(prevention OR risk factor OR epidemiology OR prevalence OR 
incidence OR seroprevalence OR seroincidence OR seroconversion 
OR genotype OR coinfect*) AND (needle exchange OR needle 
exchange program OR syringe exchange program OR syringe 
access program) AND ("1989/01/01"[Date - Publication] : 




Ottawa Quality Assessment Scale (NOS).28  Consistent with previous research, no 
study will be excluded based on the risk of bias assessment.29   
2.1.5   Statistical Analysis 
The a priori plan is to conduct an aggregate data meta-analysis with the study as 
the unit of analysis. The primary outcome for this study is the association between HCV 
seroconversion (dependent variable) and participation in a NEP (independent 
variable) observed in either cohort studies that follow seronegative individuals over time 
or case-control studies. This outcome will be calculated as the log odds ratio (OR) or 
the log hazard ratio (HR).  Because HRs include a time component, ORs and HRs will 
be analyzed separately, as recommended.30  If reported, adjusted effects will be used 
as the primary outcome under the assumption that such effects have been adjusted for 
potential bias.  Effect size estimates from individual studies will be pooled using a 
random effects model, which incorporates between study variance into the overall 
estimate.31  Between study heterogeneity will be evaluated using the Q statistic, and the 
percentage of variation in effect estimates due to heterogeneity will be assessed using 
the I2 statistic.32  Effect sizes will be calculated after each study is removed from the 
model in order to assess the influence of each study on the overall results.  Cumulative 
meta-analysis, ranked by year of publication, will be conducted to examine the accrued 
results over time. Ninety-five percent confidence intervals that do not cross ‘1’ will be 
considered statistically significant with values below 1 indicative of a decrease in the 
odds or risk of HCV seroconversion (evidence of a protective or positive effect).  
Values significantly above ‘1’ will be considered to indicate a harmful or negative 




participation on the prevention of HCV infection.  All analyses will be carried out using 
Comprehensive Meta-Analysis® (version 3.0).33 
2.2    Specific Aim #2   
Conduct a qualitative case study of two rural NEPs to identify programmatic 
facilitators, barriers, and innovative solutions. 
Research Questions:  What are the facilitators and barriers to opening the 
program?  What are the facilitators and barriers encountered during the day-to-
day running of the program?  What are the future plans for the program, and 
what are challenges and barriers related to these future plans?   
2.2.1   Study Design and Sampling    
A multiple, intrinsic case study approach has been selected for the following 
reasons:  1) each case (NEP) is of interest in and of itself (intrinsic),34  2) the goal of this 
study is to obtain an in-depth understanding of each case,35 and  3) each program 
(case) is a bounded system.35  Each case is located in West Virginia and was selected 
using a purposive sampling strategy.36  More specifically, a NEP operated within a free 
healthcare clinic and a NEP operated within a health department were purposefully 
selected to document variations between these two program structures.  
2.2.2   Qualitative Interviews   
In-depth interviews with each NEP director will be conducted.  Other NEP staff 
and individuals within the community that are recommended by the NEP director will 
also be interviewed.  Prior to conducting the interview, a structured interview guide will 
be developed.  This guide will focus on the facilitators and barriers encountered during 




questions included in the interview guide will be informed by initial discussions with 
each director, and include questions of interest to him or her.  Finally, a case study of 
the first NEP in the United States, Point Defiance,37 will also serve as a source of 
potential questions.  Due to the interest in obtaining an in-depth understanding of 
programmatic facilitators and barriers from the viewpoint of the participants, each 
interview will be semi-structured to allow conversations to emerge and flow in 
naturalistic directions that may depart from the interview guide.38  Each interview will be 
recorded using a TasCAM DR-05® stereo handheld microSD card recorder with built-in 
omnidirectional microphones.39  At various points throughout each interview, the 
interviewer will summarize the discussion and seek clarification from the interviewee 
regarding the accuracy (validity) of the measurement.  As recommended, policy and 
procedure manuals and websites will also be analyzed to triangulate emerging 
themes.40  
2.2.3   Data Analysis  
Each interview will be professionally transcribed verbatim and entered into 
NVIVO® 11 Pro software for analysis.41  Prior to formal analysis, each transcript will be 
read several times independently by two researchers with notes made regarding initial 
codes.  Next, line by line coding will be conducted with the objective of identifying 
emergent categories and themes.  The initial codebook will have a priori codes for past, 
present, and future, in which information on barriers and facilitators corresponding to 
each time period will be categorized.  In the constructivist tradition,38 codes will be 
allowed to emerge from the data prior to categorization into themes to promote 




similarities, differences, and emerging themes both within and between the two cases.40  
After initial coding and classification, intensive group discussion with a second 
researcher with a goal of simple consensus will be employed to finalize the codes and 
overall themes.42-44  If needed, discrepancies will be resolved by a third party.  This 
approach is recommended by several methodologists in order to preserve the 
interpretive process at the core of qualitative analysis,45 and is consistent with current 
case study practice,46 in specific, and qualitative research reporting criteria,47 in general.  
Naturalistic generalizations will be made by comparing emergent themes with previously 
published literature.35  
2.3   Specific Aim #3  
 
  Use a mixed-methods approach to identify self-reported barriers to using a clean 
needle among PWIDs attending NEPs in West Virginia. 
Hypothesis:  Fear of arrest and drug withdrawal will be the most frequently 
reported barriers to using a clean needle. 
2.3.1   Study Design  
  We propose to use a mixed methods approach to explore barriers to using a 
clean needle as reported by attendees of the first two NEPs to operate in West Virginia. 
2.3.1.1 Qualitative interviews   
  There are no known validated surveys to assess barriers to using a clean needle 
among PWIDs. Therefore, we propose to modify the Barriers to Using New Needles19 
survey (Figure 3) and create a standardized survey to ensure that all respondents 
answer the same set of questions (i.e., reliability).48  To further enhance survey reliability 




from which attendees will be 
sampled. Modifications will be 
made to survey questions to 
maximize their applicability to 
the rural setting and avoid 
poorly defined words or terms 
that are not universally 
understood.48  Next, 3 to 5 
attendees at each NEP will be 
purposively selected and 
interviewed using methods 
similar to the technique of 
respondent debriefings.49  
Specifically, each attendee 
will be queried about survey 
comprehension and 
completeness.50  These 
attendees will also be asked 
questions constructed from the emergent themes identified in Aim #2 to achieve 
triangulation and thematic saturation.  Final modifications based on these attendee 
interviews will be made in preparation for survey administration.   
Basic demographic questions, along with questions querying injection history 
(e.g., frequency of injecting, years of injecting, etc.) will be included in the survey. To 
Figure 3.  Barriers to Using New Needles19  
 
1. It takes too long to get a new 
needle every time I inject.* 
2. It is inconvenient to get a new 
needle every time I inject. 
3. I often don’t want to take the time 
to get a new needle because my 
cravings or urges to use drugs 
are too strong. 
4. I often do not take the time to get 
a new needle if I am drug sick or 
in withdrawal. 
5. I don’t take the time to get a new 
needle before injecting because I 
can only think about getting high. 
6. I don’t take the time to get a new 
needle before injecting if I’m 
already high or drunk. 
7. The places where I inject usually 
do not have access to new 
needles. 
8. If I am in a shooting gallery, I 
often do not use a new needle. 
9. I often do not carry new needles 
with me when I’m out. 
10. There isn’t a needle exchange 
close by for me to get needles. 
11. Pharmacies sometimes give me 
hassle when I try to buy needles. 
12. After I inject, I don’t prepare in 
advance by getting new needles 
ready for my next injection. 
13. It’s too expensive to buy new needles 
from the pharmacy for every time I 
inject. 
14. Feeling sad or depressed would get in 
the way of my using a new needle 
every time I inject. 
15. It is embarrassing to buy needles at 
the pharmacy. 
16. I worry that someone (friends, family, 
etc.) may see me buying needles at 
the pharmacy. 
17. My peers/friends would look at me 
funny if I used a new needle every 
time I inject. 
18. Having to worry about using a new 
needle interrupts the ritual of using. 
19. I am unlikely to use a new needle if a 
friend lets me borrow his or her used 
needle. 
20. I could get in trouble from the police if 
I carry needles around with me. 




minimize potential bias stemming from participant and item nonresponse, the final 
survey will be designed and pilot tested to take no more than a few minutes to 
complete.50,51  Importantly, to minimize social desirability bias given the sensitive nature 
of the questions, the survey will be anonymous.48  Given the unstable and transient 
nature of the target population, and based on consultation with the NEP program 
directors, a convenience sample of attendees conducted over a few, consecutive 
exchange days is proposed. To further promote the number of responses, participants 
will be personally invited by study staff to take the survey while attending the 
exchange.51   
2.3.1.2 Quantitative analysis   
All survey data will be entered into JMP® 13.0 Pro.52  Frequencies and 
descriptive statistics will be calculated. Contingency table analysis will be used to 
explore associations between various demographic and injection history factors and 
individual barriers to clean needle use.  An alpha of 0.05 has been selected as the 
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Needle exchange programs for the
prevention of hepatitis C virus infection in
people who inject drugs: a systematic
review with meta-analysis
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Abstract
Background: Previous research on the effectiveness of needle exchange programs (NEP) in preventing hepatitis C
virus (HCV) in people who inject drugs (PWID) has shown mixed findings. The purpose of this study was to use the
meta-analytic approach to examine the association between NEP use and HCV prevention in PWIDs.
Methods: Study inclusion criteria were (1) observational studies, (2) PWIDs, (3) NEP use, (4) HCV status ascertained
by serological testing, (5) studies published in any language since January 1, 1989, and (6) data available for measures
of association. Studies were located by searching four electronic databases and cross-referencing. Study quality was
assessed using the Newcastle Ottawa (NOS) scale. A ratio measure of association was calculated for each result from
cohort or case–control studies and pooled using a random effects model. Odds ratio (OR) and hazard ratio (HR)
models were analyzed separately. Results were considered statistically significant if the 95% confidence interval
(CI) did not cross 1. Heterogeneity was estimated using Q and I2 with alpha values for Q ≤ 0.10 considered
statistically significant.
Results: Of the 555 citations reviewed, 6 studies containing 2437 participants were included. Studies had an
average NOS score of 7 out of 9 (77.8%) stars. Concerns over participant representativeness, unclear adjustments
for confounders, and bias from participant nonresponse and loss to follow-up were noted. Results were mixed
with the odds ratio model indicating no consistent association (OR, 0.51, 95% CI, 0.05–5.15), and the hazard ratio
model indicating a harmful effect (HR, 2.05, 95% CI, 1.39–3.03). Substantial heterogeneity (p ≤ 0.10) and moderate
to large inconsistency (I2 ≥ 66%) were observed for both models.
Conclusions: The impact of NEPs on HCV prevention in PWIDs remains unclear. There is a need for well-designed
research studies employing standardized criteria and measurements to clarify this issue.
Trial registration: PROSPERO CRD42016035315
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Globally, over 184 million people (>2.8% of the world’s
population) have been infected with the hepatitis C virus
(HCV) [1]. HCV is a blood-borne virus that infects the
liver. Approximately 75% of acute HCV infections be-
come chronic [2]. Chronic HCV infection significantly
increases the risk of liver disease, especially cirrhosis and
liver cancer [1–7]. A majority of the 350,000 deaths attrib-
uted to HCV infection each year are caused by cirrhosis
and hepatocellular carcinoma [7]. In most countries, the
annual incidence of HCV infection has peaked with the
exception of Russia where new cases are still increasing
[1]. However, a troublesome pattern of new HCV cases
observed in the USA suggests another or recurrent public
health epidemic [1, 2, 8, 9].
The incidence of HCV in the USA declined from
2000–2005 and plateaued during 2005–2010 [8]. There-
after, the number of reported acute cases increased sig-
nificantly with a 2.6-fold increase observed between
2010 and 2014 [8]. Collectively, a 364% increase in HCV
cases among persons aged ≤30 years was observed in
Central Appalachia (Kentucky, Tennessee, Virginia, and
West Virginia) between 2006 and 2012 [10]. As a result,
the USA has set a goal of reducing new hepatitis C in-
fections from 0.28 cases per 100,000 to 0.25 cases per
100,000 (Healthy People 2020 Objective IID-26) [11].
HCV-infected patients consume a large proportion of
healthcare resources in the USA. Between 2001 and 2010,
HCV-infected individuals accounted for almost 3 million
outpatient, inpatient, and emergency department visits in
the USA [6]. Estimated healthcare costs associated with
the treatment and care of chronic HCV was $6.5 billion in
2011 and is expected to peak at $9.1 billion in 2024 [3].
Although HCV can be transmitted in several ways, the
primary mode of HCV exposure is percutaneous with
injection drug use remaining the largest risk factor for
HCV infection [2, 3, 8, 9, 12–18]. People who inject
drugs (PWID) account for approximately 60–70% of the
incidence of new HCV infections in the USA and many
other countries [2]. Globally, it is estimated there are 10
million PWIDs that have HCV infection [18]. The preva-
lence of HCV infection in PWIDs ranges between 40
and 90% and has been observed to be as high as 98%
[10]. Recent evidence from the USA has shown that
many of these PWIDs are White [2, 9, 14, 15] and young
(<35) [2, 8, 9, 14, 15] and have a history of prescription drug
use and abuse, especially prescription opiates [2, 13–15].
Furthermore, two recent studies suggest that HCV-
infected PWIDs are more likely to reside in non-urban
areas [14, 15].
Harm reduction interventions aim to reduce individual
and societal harms stemming from drug use by targeting
risky behaviors and risky settings [19]. A needle exchange
program (NEP) is one popular harm reduction interven-
tion that seeks to reduce risky settings. NEPs provide
clean needles in exchange for used needles to minimize
the reuse of needles contaminated with infectious disease
during drug injection [19]. Many NEPs also provide other
prevention materials and services such as additional sterile
injecting supplies (e.g., cotton and alcohol swabs), wound
care and safe injecting practices education, and linkage
and referral to substance treatment programs for those
PWIDs ready to quit injecting [20]. However, the evidence
for the effectiveness of NEPs in preventing HCV among
PWIDs is mixed [21]. For example, a systematic review
with meta-analysis of several interventions, including
NEPs, to prevent HCV infection in PWIDs observed an
increased risk of HCV seroconversion associated with
NEP use (RR 1.62, 95% CI, 1.04–2.52), although sub-
stantial heterogeneity was observed (Q = 32.3; P < 0.01;
I2 = 81%) [12]. Furthermore, this systematic review only
included studies published through April 2010, and se-
lected studies were limited to the injection of illegal
drugs (heroin, amphetamine, and cocaine) by PWIDs.
Thus, studies describing the injection of prescription
opioids were not considered for inclusion in the analysis.
In another study, a review of reviews by MacArthur et al.
[21] concluded that there was insufficient evidence to sup-
port or discount the effectiveness of NEPs for the preven-
tion of HCV in PWIDs. A more recent systematic review
of needle/syringe programs for the reduction of HCV in-
fection among PWIDs by Abdul-Quader et al. [22] found
that 6 of the 15 included studies (40%) reported decreases
in HCV infection. However, included studies only exam-
ined structural and population level interventions, as op-
posed to the association between individual use of NEPs
and HCV infection. Finally, a recently published system-
atic review with meta-analysis by Sawangiit et al. [23] ex-
amined the effectiveness of pharmacy-based NEPs for
PWIDs. However, in addition to specifically focusing on
pharmacy-based NEPs, which may not always exchange
needles [24], this study only examined the impact of these
programs on the prevalence of HCV versus the prevention
of new infections (incidence). To the best of the authors’
knowledge, no other systematic reviews with or without
meta-analyses of the effectiveness of NEPs in preventing
HCV in PWIDs currently exist. Therefore, the primary
objective of this study was to conduct a systematic review
with meta-analysis to examine the association between
NEPs and the prevention of HCV in PWIDs.
Methods
General procedure
The conduct and reporting of this study followed the
recommended guidelines from the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis
(PRISMA) statement [25]. This systematic review with
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meta-analysis is registered in the PROSPERO trial
registry (CRD42016035315).
Study eligibility criteria
The a priori inclusion criteria for this systematic review
with meta-analysis were as follows: (1) observational
studies, (2) PWIDs, (3) NEP use, (4) HCV status ascer-
tained by serological testing (saliva or serum), (5) studies
published in any language after January 1, 1989, and (6)
data available or calculable for measures of association
between participation in a NEP and HCV infection.
Studies were excluded based on inappropriate study
design, population, intervention, or lack of available in-
formation to calculate a measure of association between
program participation and HCV infection.
Although randomized controlled trials are considered
the highest level of evidence for examining the effect of
an intervention on a health outcome, [26] it was antici-
pated that no such trials would be found given that it
would be highly unethical (violation of the ethical
principle of beneficence) to randomize subjects away
from a potentially beneficial treatment (i.e., needle ex-
change). Therefore, the focus of the review was on ob-
servational studies.
An a priori decision was made to exclude studies that
reported the use of supervised injection facilities (SIFs).
The rationale for this exclusion was based on the obser-
vation that while SIFs provide a safe environment for
drug users to inject drugs, such facilities may not always
provide (exchange) clean needles [27]. Additionally,
studies describing the distribution of clean syringes from
pharmacies were also excluded because such programs
typically involve the sale of clean syringes with or with-
out a prescription but may not involve the exchange of
clean needles for dirty needles [24]. HCV status ascer-
tained by serological testing was chosen as the primary
outcome because previous research has demonstrated
low sensitivity when HCV status is self-reported by
PWIDs [28]. The year 1989 was chosen as a starting
point for the search because this was the year that the
HCV antibody was identified, and thus, enabled sero-
logical testing to detect the virus [29]. Based on the rec-
ommendations by van Driel et al. [30], no searches for
unpublished works such as dissertations and conference
abstracts or other unpublished reports were conducted.
Data sources
The following databases were searched between July 18,
2016, and August 24, 2016: (1) PubMed, (2) Scopus, (3)
Web of Science, and (4) CINAHL. The search strategy
and terms were based on the work of the HCV synthesis
project [29] and was modified to include specific search
terms related to NEP that were used by Abdul-Quader
et al. [22] in their systematic review of population level
outcomes following the implementation of NEP. Addi-
tionally, the term “people who inject drugs” was included
in the search given the observation by the authors that
this term has been commonly used to refer to injection
drug users in more recent research literature. Although
there was slight variation in the specific search format
between databases, the following search terms and
combinations were used: (hepatitis C OR HCV) AND
(intravenous drug abuse OR intravenous drug use OR
drug misuse OR drug addict OR injecting drug use OR
drug abuse OR people who inject drugs OR PWID OR
PWID) AND (prevention OR risk factor OR epidemi-
ology OR prevalence OR incidence OR seroprevalence
OR seroincidence OR seroconversion OR genotype OR
coinfect*) AND (needle exchange OR needle exchange
program OR syringe exchange program OR syringe access
program) AND (“1989/01/01” [Date - Publication] : “3000”
[Date - Publication]). Search strategy examples for the four
databases searched are included in Additional file 1. In
addition to database searches, cross-referencing from
retrieved studies and reviews was also conducted. After
identifying the final number of studies to be included,
the number needed to read (NNR) was calculated by
taking the inverse of the precision, which was defined
as the number of included studies divided by the total
number of studies screened after removal of duplicates
[31]. All studies identified during the search were
stored in EndNote® version 7.4 [32].
Study selection
Two researchers (SMD and SD) independently reviewed
studies for selection and abstracted data from eligible
studies with discrepancies resolved by consensus and dis-
cussion with a third researcher (GK), if needed. Duplicate
studies were discovered by using the “Find Duplicates”
tool in EndNote® 7.4 [32] and by manual examination.
After removal of duplicate studies, abstracts of all studies
were reviewed and the full text of studies appearing to
meet the inclusion criteria were obtained and reviewed.
Studies that met all of the inclusion criteria were selected.
The authors were not blinded to journal titles and study
authors and their associated institutions during the review.
Reasons for exclusion from further review were coded as
one or more of the following: (1) inappropriate population
(i.e., not PWIDs), (2) inappropriate intervention (i.e.,
not a NEP), (3) inappropriate comparison (i.e., no com-
parison to non-exchange users), (4) inappropriate out-
come (i.e., self-reported HCV status), and (5) lack of
data to enable calculations of the association between
program use and HCV infection.
Data abstraction
A codebook containing 85 items was developed a priori
using Microsoft Excel 2013®, [33] and is included in
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Additional file 2. The major categories of variables coded
by the authors were based upon the HCV Synthesis
Project [29] and included (1) study characteristics (author,
journal, year, funding status, design, inclusion criteria,
recruitment method, recruitment locations, method of
determining PWID status, specimen type, and HCV test
method), (2) participant characteristics (age, gender,
ethnicity, duration of drug use, type of drug used, fre-
quency of use), and (3) outcome characteristics (preva-
lence, incidence, number of person years, sample size, and
variables adjusted for, if applicable). The primary outcome
of this study, established a priori, was the association
between HCV seroconversion and use of a NEP.
Risk of bias assessment
The risk of bias in selected studies was assessed using
the Newcastle-Ottawa Quality Assessment Scale (NOS)
[34]. Consistent with previous research, no study was ex-
cluded based on the risk of bias assessment [35].
Statistical analysis
The a priori plan was to conduct an aggregate data
meta-analysis with the study as the unit of analysis.
Calculation of effect sizes
The primary outcome for this study was the association
between HCV seroconversion and participation in a
NEP observed in either cohort studies that follow sero-
negative individuals over time to monitor seroconversion
or case–control studies. This outcome was calculated as
the log odds ratio (OR) or the log hazard ratio (HR).
Because hazard ratios include a time component, ORs
and HRs were analyzed separately.
Where possible, published ratios (OR or HR) and con-
fidence limits from individual studies were used to cal-
culate the log ratios and corresponding logs of the
standard errors. If associations in individual studies were
not presented in ratios, only log odds ratios were calcu-
lated using the reported number of HCV infections and
the total number of participants in each group (NEP
users and non-users). Missing log hazard ratios were not
calculated due to the unavailability of time data. If an
exact p value was reported instead of a confidence inter-
val (CI), the standard error was calculated using the
following formula [26]: log(OR)/z. If reported, adjusted
effects were used as the primary outcome under the as-
sumption that such effects have been adjusted for poten-
tial bias in the observed association between NEP
participation and HCV infection. For ease of interpret-
ation, log ratios were converted back to odds ratios and
hazard ratios after analysis.
Pooling estimates
Effect size estimates from individual studies were pooled
using a random effects model [36]. Between-study het-
erogeneity was evaluated using the Q statistic, and the
percentage of variation in effect estimates due to hetero-
geneity was assessed using the I2 statistic [37]. Based on
current recommendations, heterogeneity was considered
to be substantial if the p value for the observed Q statis-
tic was ≤0.10 [26]. The amount of heterogeneity present
(as assessed by I2 values) was interpreted according to
the following categories: <25% (“very low”); 25 to <50%
(“low”); 50 to <75% (“moderate”); and 75% or greater
(“large”) [37]. Effect sizes were calculated after each
study was removed from the model in order to assess
the influence of each study on the overall results. In
addition, cumulative meta-analysis, ranked by year of
publication, was conducted to examine the accrued re-
sults over time. Ninety-five percent confidence intervals
that did not cross 1 were considered to be statistically
significant with values below one indicative of a decrease
in the odds or risk of HCV seroconversion (evidence of
a preventative or positive effect). Values significantly
above one were considered to indicate a harmful or
negative effect. Values that crossed 1 were considered to
indicate no effect from NEP participation on the preven-
tion of HCV infection.
An a priori plan was made to assess small-study effects
(publication bias, etc.) using funnel plots and Egger’s re-
gression intercept test (one-tailed). However, we were
unable to conduct these analyses because we did not
have at least 10 effect sizes, the minimum sample size
recommended by Sterne et al. [38]. Similarly, a priori
plans to conduct a mixed-effects meta-regression to
examine potential covariates and a moderator analysis to
examine potential differential study effects from different
study designs (e.g., cohort and case study) were not con-
ducted due to insufficient sample sizes (<10 effects) [26].
All analyses were carried out using Comprehensive
Meta-Analysis (version 3.0) [39].
Results
Study characteristics
Overall, of the 555 references examined, 6 studies,
[40–45] containing data from 2437 PWIDs, were in-
cluded in the final review and analysis. One study [46]
was identified that contained estimates based on data
from the same sample of PWIDs collected in the same
location during the same time periods as those in-
cluded in another larger and more recent study that
was selected for inclusion [42]. Therefore, this study
was eliminated from analysis given that these data would
have violated the statistical requirement of independence
of effect size estimates. The precision of the search was
1% (6/555), and the NNR was 100. Figure 1 diagrams the
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search process and includes reasons for the exclusion of
various studies from the final analysis. Table 1 lists the
general study characteristics. Half of the studies were con-
ducted in the USA [40–42], followed by two conducted in
Canada [43, 44], and one conducted in Afghanistan [45].
Without exception, all studies were conducted in densely
populated urban locations. All studies were published in
the English language. There was one case–control study
[40] and five cohort studies [41–45].
Participant characteristics
All studies enrolled PWIDs who self-reported injections.
However, time since last injection prior to enrollment
varied between studies with two studies enrolling partici-
pants that had injected in the previous month [43, 45],
one study enrolling those that injected in the previous
6 months [44], one study enrolling those that had injected
in the past year [41], one study containing a mix of partici-
pants who injected in the previous 6 months and 1 year
[42], and one study not specifying any length of prior
injection [40].
Participants were enrolled in a variety of settings ran-
ging from syringe exchange programs, [44] harm reduc-
tion programs which provided motivational counseling,
washing facilities, medical care, and infectious diseases
testing in addition to syringe distribution [45], emer-
gency rooms [40], county health departments [40], jails
[41], streets [41–43], social service agencies [41], and
areas of known drug user congregation [45].
A variety of sampling schemes were described including
respondent driven [42], criterion [40], convenience [44],
random [41], and a variant of time-location sampling [45].
One study did not describe the sampling strategy [43].
Study participants were recruited over two decades with
the oldest study recruiting during 1991 to 1993 [40] and
the most recent study enrolling participants between June
2007 and March 2009 [45].
Of the 2437 PWIDs, 941 reported participation in a nee-
dle exchange program (“NEP users”) and 946 participants
did not report using a needle exchange (“non-users”). Two
studies did not report needle exchange participation for
the number of participants who were HCV seronegative at
Fig. 1 Flow diagram for the selection of studies. *Number of reasons exceeded the number of studies because some studies were excluded for
more than one reason
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baseline [44, 45]. With the exception of one study that
only enrolled males [45], all other studies enrolled both
genders. The percentage of male participants in these
studies ranged from a low of 42.3% [40] to a high of 73%
[44] with an average of 62%. Participants in all studies
were generally young (<40 years). However, reporting of
age was variable with the average given in one study
(31.8 years [44]), medians in two studies (28 years [43, 45]),
and age categories in the remaining three studies [40–42].
In these latter three studies, the proportion of all partici-
pants less than 34 years of age was at least 65%.
There was a wide variability in the reporting of partici-
pant race and/or ethnicity with two studies [44, 45] not
reporting any race and/or ethnicity. Of the five studies
reporting race and/or ethnicity, “White” race was the
most frequently reported by participants, ranging from a
low of 49% [42] to a high of 85% [40].
The types of drugs injected varied between studies.
The most frequent drugs injected, self-reported by
participants in each study, included heroin [41, 43] and
cocaine [44]. Three studies [40, 42, 45] did not report a
specific type of drug.
Length of time injecting was also widely variable
between studies. Three studies reported median injecting
durations of 2 years [42, 45] and 7 years [43]. Another
two studies partitioned injecting duration into categories.
Hagan et al. [40] reported the following categories: HCV
positive cases: <5 years (n = 7, 35%), 5+ years (n = 13,
65%); HCV negative controls: <5 years (n = 6, 23.1%),
5+ years (n = 20, 76.9%). Hagan et al. [41] reported
the following categories (years): ≤1 (n = 57, 13%), 1.1
to 2.0 (n = 76, 16%), 2.1–5.0 (n = 144, 32%), 5.1–10.0
(n = 84, 19%), >10.0 (n = 93, 20%). Roy et al. [44] re-
ported an average of 10 years of injecting.
Half of the studies did not report any information re-
lated to the frequency of injections [40, 44, 45]. In the
three studies reporting injection frequency [41–43], the
proportion of participants injecting at least once a day
averaged 51.03%.
Intervention characteristics
Participation in a NEP was assessed by self-report in all
six studies. The frequency of participation varied between
studies due to heterogeneity in the presentation of results.
Two studies reported ever (versus never) using a NEP
[40, 41]. Two studies reported NEP use in the last
3 months [42, 45]. Three studies reported NEP use in
the last 6 months [42–44], with Patrick et al. [43] re-
quiring NEP attendance at least once per week in the
past 6 months.
Risk of bias assessment
Risk of bias assessment results are shown in Table 2. In-
dividual study scores ranged from 5–8 stars, which
represented 55–89% of the total number of stars that
can be awarded (9 stars). The five cohort design stud-
ies [41–45] averaged 7 stars with the lone case–con-
trol study [40] receiving 6 stars.
Four of the six studies [41–43, 45] received the max-
imum number of stars (4) in the selection category. Con-
cerns over the representativeness of participants resulted
in the deduction of one star from this category in the
remaining two studies [40, 44]. All but two of the studies
received the maximum number of stars (2) in the compar-
ability category. Patrick et al. [43] and Roy et al. [45] each
received only one star in this category because adjustments
for potential confounders were unclear. No studies re-
ceived the maximum number of three stars in the assess-
ment of the exposure (case–control) or outcome (cohort)
category. Potential bias from participant nonresponse and
loss to follow-up was a primary weakness for all studies.
Primary outcome
Study outcomes are shown in Table 3. Four studies
reported (or had data enabling calculation of) hazard ra-
tios [41, 43–45], with two studies reporting odds ratios
[40, 42]. Three studies [40, 42, 43] adjusted effect esti-
mates for potential confounders. Overall, findings were
mixed. A statistically significant harmful effect from par-
ticipation in NEPs was observed when the four studies
that reported hazard ratios were combined (pooled HR,
2.05, 95% CI, 1.39–3.03, Fig. 2a). However, significant
heterogeneity and moderate inconsistency were observed
(Q = 9.03; p = 0.029; I2 = 66.8%). This finding was not in-
fluenced by the deletion of any study from the model
once (Fig. 2b) and remained consistent over time
(Fig. 2c), with all cumulative results yielding confidence
intervals that did not cross 1. In contrast, there was no
significant association between the odds of HCV sero-
conversion and participation in a NEP when the two
studies that reported odds ratios were combined (pooled
OR, 0.51, 95% CI, 0.05–5.15, Fig. 3), although both sig-
nificant heterogeneity and large inconsistency between
studies were observed (Q = 8.66; p = 0.003; I2 = 88.4%).
Influence analysis and cumulative meta-analysis were
not conducted on the odds ratio model given the inclu-
sion of only two studies.
Table 2 New-Castle Ottawa Scale Ratings
Study Selection Comparability Exposure/Outcome
Hagan 1995 [40] ★★★ ★★ ★
Hagan 2004 [41] ★★★★ ★★ ★★
Holtzman 2009 [42] ★★★★ ★★ ★
Patrick 2001 [43] ★★★★ ★ ★★
Roy 2007 [44] ★★★ ★ ★
Todd 2015 [45] ★★★★ ★★ ★★
Davis et al. Harm Reduction Journal  (2017) 14:25 Page 7 of 15
21
Discussion
The primary purpose of this systematic review with
meta-analysis was to assess the potential effect of NEP
on the prevention of HCV infection in PWIDs. The
overall findings were mixed and suggest that NEP could
either increase the risk of HCV infection in PWIDs or
have no effect. This interpretation is supported by (1)
pooled results from studies reporting a hazard ratio that
indicate a harmful effect (pooled HR, 2.05, 95% CI,
1.39–3.03), (2) pooled results from studies examining
the odds of infection that do not indicate either a prevent-
ive benefit or harmful effect (pooled OR, 0.51, 95% CI,
0.05–5.15), and (3) substantial heterogeneity (p ≤ 0.10)
and moderate (I2 = 67%) to high (I2 = 88%) inconsistency
observed for both models. These mixed findings are con-
sistent with previous research.
A review of reviews without meta-analysis by MacArthur
et al. [21] of interventions to prevent HCV in PWIDs iden-
tified 17 studies with mixed results (9 positive, 2 negative,
and 6 no effect) leading to the conclusion that there was
insufficient evidence to either support or discount the ef-
fectiveness of NEP for preventing HCV.
Hagan et al. [12] conducted a systematic review with
meta-analysis of the effectiveness of interventions, in-
cluding NEP, on the prevention of HCV. Similar to the
results from our hazard ratio model, this meta-analysis
observed a 62% increase in the risk of HCV seroconver-
sion from participation in syringe access programs (RR,
1.62, 95% CI, 1.04–2.52) with substantial heterogeneity
and large inconsistency (Q = 32.3, I2 = 81%). Included
studies contained a mixture of no effect (three studies),
positive (one study), and harmful (three studies) results.
Five of these seven studies were included in our meta-
analysis. A single-site study by Thorpe et al. [46] which
observed no effect (HR, 1.29, 95% CI, 0.6–2.79) from
NEP participation on HCV infection contained data that
were also included in the Holtzman et al. [42] multi-site
study. Therefore, we excluded this study from the final
model to maintain the criterion of independence of
effect sizes. Despite extensive searching and multiple
electronic and personal queries, we were unable to lo-
cate a governmental report by Lamonthe et al. [47] for
review and possible inclusion in our systematic review
with meta-analysis. Hagan et al. [12] reported that this
study demonstrated a harmful effect (HR, 2.24, 95% CI,
1.01–4.98). The current review included one additional
cohort study [45], published in 2015, that observed a
harmful effect.
A recently published systematic review with meta-
analysis of pharmacy-based NEP demonstrated a 74% re-
duction in the odds of HCV infection (OR = 0.26, 95%
CI, 0.18, 0.38) associated with pharmacy-based NEP par-
ticipation [23]. However, the authors cautioned that this
finding was unclear due to the very small number of
included studies (n = 2) and significant bias concerns.
Observed heterogeneity in the study population, and
variability in defining the intervention and outcomes re-
ported, further precluded the ability to draw definitive
conclusions between HCV infection and pharmacy-
based NEP participation. This observation is consistent
with the current review. Indeed, the substantial hetero-
geneity and large inconsistency observed in both the
current study and the previous meta-analyses may be
related to important between-study differences in the
population enrolled, intervention examined, outcome
assessed, and type of study design (and associated statis-
tical analyses).
Variable populations
All studies included in the current review, with the not-
able exception of Todd et al. [45], enrolled a mix of
genders that were largely under the age of 40 and White.
However, all studies had slightly different age require-
ments with some studies enrolling PWIDs as young as
14 years [41] and 15 years [43] compared to other
studies that did not report a limit on age [40, 44], only
enrolled adults (≥18 years [45]), or had varying age range
requirements (e.g., 18–30 and 18–40) [42]. Furthermore,
Table 3 Study outcomes and adjustments
95% CI
Study Outcome Adjusted Adjustments Estimate Lower Upper p
Hagan 1995 [40] Odds ratio y Sex, race/ethnicity, duration of
drug injecting
0.14 0.03 0.62
Hagan 2004 [41] Hazard ratio n 1.40 0.90 1.90
Holtzman 2009 [42] Odds ratio y Sex, age in years, race/ethnicity,
education, source of income, site,
study time period, injection risk
behaviors, and HIV serostatus
1.49 0.96 2.29
Patrick 2001 [43] Hazard ratio y Not described 2.56 1.37 4.79
Roy 2007 [44] hazard ratio n 3.02 0.18
Todd 2015 [45] Hazard ratio n 1.72 1.07 2.76
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there were a variety of settings in which PWIDs were re-
cruited over an almost 20-year timeframe. However, with
the exception of Todd et al. [45], all included studies
were conducted in North America. Importantly, no
studies took place in the rural, Central Appalachian re-
gion of the USA, an area that is in the midst of a hepatitis
C epidemic that is directly related to increasing prescrip-
tion opioid abuse and injection of heroin [48, 49].
Additionally, injection use appeared to be entirely self-
reported in all studies, and there were variances in the
length of time from last injection criterion between
studies, with some studies enrolling individuals who re-
ported ever injecting [40] to other studies only enrolling
individuals who injected at least once in the previous
month [43, 45].
Variable interventions
Participation in NEP was self-reported in all studies.
However, the frequency of attendance was highly vari-
able between studies, ranging from questions querying
Fig. 2 a Forest plot for the risk of hepatitis C infection among needle exchange program participants. The black squares represent the risk of
hepatitis C infection observed in each study with the 95% confidence intervals represented by the lines on each side of the squares. The diamond
represents the pooled risk of hepatitis C infection with the 95% confidence interval indicated by the left and right extremes of the diamond. b Influence
analysis for the risk of hepatitis C infection among needle exchange program participants. Influence analysis for point estimate changes in the risk of
hepatitis C infection with each individual study deleted from the model once. c Cumulative meta-analysis for the risk of hepatitis C infection
among needle exchange program participants. The results of each corresponding study, ordered by year of publication from oldest to newest,
are pooled with all studies preceding it
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whether or not a program had ever been used [40, 41] to
NEP attendance at least once per week in the previous
6 months [43]. No pattern between study findings and
reported frequency of attendance was observed.
Variable outcomes
Although all studies included a serological measure of
HCV, one study demonstrating a harmful effect used
saliva measurements [44], which may vary in accuracy
compared to serum tests. Additionally, the particular
assay used in the serum measurements was variable with
some studies using second-generation assays and others
using third-generation assays.
Variable study designs and analyses
The particular type of outcome assessed was directly re-
lated to variability in study design and the associated
outcomes. In the current review, cohort studies that in-
corporated a time component into the analysis and re-
ported hazard ratios, demonstrated a significant increase
in the risk of HCV infection for NEP users; whereas, the
lone case–control study [40] that reported an odds ratio
demonstrated a highly significant preventative effect
from NEP use. In contrast, Holtzman et al. [42] analyzed
data from a combination of observational cohort studies
and a subset of data from a randomized behavioral inter-
vention, and reported an odds ratio that demonstrated
no significant effect from NEP participation on the
prevention of HCV. These differences in outcomes pre-
cluded the ability to combine all effect sizes into one
model and instead resulted in two models with different
interpretations. Although this plan differs from the com-
bined model presented by Hagan et al. [12], we made
this decision a priori based on the rationale that odds ra-
tios and hazard ratios are two fundamentally different
measures, given that the latter incorporates a time com-
ponent (i.e., time-to-event data). Although not recom-
mended, time-to-event data can sometimes be analyzed
as dichotomous data that yield odds ratios [26]. How-
ever, such an analysis requires that the status (e.g., ser-
ostatus) of all patients be known at a fixed time point
(i.e., 12 months) [26], which was not reported in all
studies included in our hazard ratio model. Further
complicating matters is that some studies made adjust-
ments to the overall reported main outcome whereas
other studies only reported unadjusted results. Among
those studies that made adjustments, different potential
confounders were controlled for likely leading to
additional heterogeneity between studies.
In a recent review of reviews, MacArthur et al. [21] re-
ported a similar pattern of variability in findings by study
design. Of the 17 studies examining the impact of NEP on
the prevention of HCV, nine studies (one case–control
study, six cross-sectional studies, and two ecological
studies) demonstrated a positive (or preventative) effect
from NEP use. In contrast, two cohort studies demon-
strated a negative (or harmful) effect. The remaining six
studies demonstrated no association and were evenly split
between three cohort studies and three cross-sectional
studies.
While we made an a priori decision to exclude cross-
sectional studies in our meta-analysis due to the fact that
such designs can only assess associations between NEP
participation and HCV infection, the current review
identified five cross-sectional studies that met all other
inclusion criteria [50–54]. Results from these studies
were mixed with one study finding no effect from NEP
participation (OR, 1.54, 95% CI, 0.73–3.24) [50], one
study finding a preventative effect (OR, 0.59, 95% CI,
0.43–0.77) [53], and three studies demonstrating a
harmful effect (OR, 2.17, 95% CI, 1.38–3.40 [51]; OR,
2.1, 95% CI, 1.54–2.89 [52]; OR, 2.54, 95% CI, 1.36–4.74
[54]). Similar to the findings from the current review,
not all studies adjusted odds ratios for confounding, and
the various adjustments made were not uniform between
studies. Qualitative heterogeneity in the measurement of
Fig. 3 Forest plot for the odds of hepatitis C infection among needle exchange program participants. The black squares represent the odds of
hepatitis C infection observed in each study with the 95% confidence intervals represented by the lines on each side of the squares. The diamond
represents the pooled odds of hepatitis C infection with the 95% confidence interval indicated by the left and right extremes of the diamond
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both the exposure (NEP use) and outcome (HCV infec-
tion) were also reported. Finally, Turner et al. [55] con-
ducted a meta-analysis of cross-sectional and cohort
studies conducted in the UK and observed no effect
from NEP participation on HCV incidence (ES, 0.58,
95% CI, 0.30–1.15). Interestingly, and in contrast to all
other studies, no inconsistency (I2 = 0.0%) was reported
in the model. The two cohort studies included in this
model did not contain data that would allow calculation
of the association between NEP use and HCV infection
(inclusion criteria #6).
HIV studies
The heterogeneity observed in this systematic review
with meta-analysis is not limited to studies examining
the effectiveness of NEP for the prevention of HCV. A
recent systematic review with meta-analysis by Aspinall
et al. [56] examining the influence of NEP on prevention
of HIV observed large inconsistency (I2 = 75.7%) between
the 12 included studies (10 cohort, 1 cross-sectional, and
1 case–control). Although a preventative effect from NEP
exposure was suggested, the upper bound of the confi-
dence interval slightly crossed 1 (pooled effect size, 0.66,
95% CI 0.42–1.01). When higher-quality studies, as graded
by the Newcastle-Ottawa Scale, were combined, a sig-
nificant preventative effect was observed (0.42, 95% CI,
0.22–0.81), although large inconsistency (I2 = 80%)
remained. Similar to the current review, variability in
study populations, measurements of the intervention
and exposure, and statistical analyses, likely contributed
to significant heterogeneity in the models. In particular,
the authors graded the overall quality of the evidence
as “low” due to considerable limitations observed in the
primary studies. Potential confounding of results from
historical threats to internal validity, especially the
introduction of antiretroviral medicines that minimize
transmissible viral load and sexual health promotion
programs, was a noted concern. Additionally, the statis-
tical power to detect a significant result was low due to
the fact that HIV seroconversions were a relatively rare
event, which is also a problem in studies examining the
role of NEP in preventing HCV seroconversion. Of
note, many of the primary studies only examined HIV
incidence as a secondary outcome.
Implications for research and practice
The previously discussed qualitative between-study dif-
ferences that may be contributing to the substantial
statistical heterogeneity and large inconsistency raise
several important implications for future research. More
specifically, there is a need for well-designed cohort
studies that follow seronegative individuals forward in
time to track potential seroconversion. It is suggested
that these studies seek standardization of interventions
and outcomes in the following areas: (1) inclusion criteria,
(2) injection use timeframe, (3) definition and measure-
ment of NEP use, (4) outcome assessment, and (5) statis-
tical analysis plan.
With regard to suggestion 3, more objective measures
of program attendance are recommended, but may be
difficult to implement in practice. In particular, some
needle exchanges do not require identification to obtain
needles [57], which precludes the ability to objectively track
program attendance. Alternatively, a randomly assigned
identification number could be implemented to track both
program attendance and any potential seroconversion.
With regard to suggestion 5, given the fact that a re-
cent meta-analysis found a 94% increased risk of HCV
seroconversion among injection drug users who shared
syringes (pooled risk ratio = 1.94, 95% confidence inter-
val (CI) 1.53, 2.46) [58], the sharing of syringes is an im-
portant covariate that should be standardized, measured,
and adjusted for in future studies. Although a recent
report by the US Centers for Disease Control (CDC)
suggested that NEPs can reduce the sharing of syringes,
White PWIDs, who are largely driving the HCV epi-
demic in nonurban areas, had the highest rate of syringe
sharing [59].
Importantly, merely providing clean needles to PWIDs
may not be enough to prevent new cases of HCV. Crofts
et al. [60] first documented new HCV infections in
PWIDs who reported no needle sharing, which suggests
that HCV infection could be spread in other ways, such
as sharing of contaminated equipment (e.g., mixing spoons
and filters). Furthermore, a recent study conducted with
heroin injectors in Denver, Colorado, observed barriers to
using a clean needle for every injection, such as being in
withdraw and fear of arrest that may prevent the use of a
clean needle for every injection [61]. However, research
examining these barriers in rural settings is nonexistent
and represents an area ripe for inquiry.
Given the mixed findings and substantial heterogeneity
and inconsistency observed in both this review and pre-
vious reviews, there is insufficient empirical evidence to
either recommend or discount NEP for the prevention
of HCV. However, despite this mixed evidence, the US
CDC recently recommended implementation of these
programs in rural areas that have been disproportion-
ately affected by the recent opioid and heroin epidemics
[59]. Unfortunately, not much is currently known re-
garding the experience of opening these programs in
rural areas. Therefore, research elucidating the unique
context in which these programs are implemented in rural
areas, as well as the challenges and barriers experienced,
is needed. To the best of our knowledge, there are cur-
rently only nine programs listed in the North American
Syringe Exchange Network that are located in Central
Appalachia (two programs in Kentucky, one in Tennessee,
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none in Virginia, and six in West Virginia) [62]. However,
this total represents eight additional programs that have
opened since June, 2014, when only one program operated
in Nashville Tennessee [63].
Strengths
There are at least six potential strengths of the current
meta-analysis. First, to the best of the author’s know-
ledge, this systematic review with meta-analysis repre-
sents the first work using meta-analytic methods to
provide quantitative estimates of the impact of NEPs on
the prevention of HCV in PWIDs since the work of
Hagan et al. [12]. The recently published systematic
review with meta-analysis by Sawangjit et al. [23] only
focused on pharmacy-based NEP and HCV prevalence
(as opposed to the prevention of incident cases). Secondly,
included studies were limited to designs which promote
drawing causal inferences (i.e., cohort and case–control).
Third, studies were not limited to the injection of illegal
drugs. Fourth, these mixed results are consistent with pre-
vious studies. Fifth, the use of an objective serological
measure of the outcome minimized potential bias in the
reporting of HCV status. Sixth, this review has led to
specific recommendations for the design of studies to
minimize between-study heterogeneity and inconsistency,
which may be preventing definitive conclusions regarding
the effect of NEPs on the prevention of HCV.
Limitations
There are at least six potential limitations to be considered
when reviewing the results of this meta-analysis. First, the
current study excluded SIFs and pharmacies from the
search due to our objective of examining the evidence
related to programs that both collect and distribute (i.e.,
exchange) needles. In contrast, SIFs primarily provide
clean needles for the injection of drugs on-site under
medical monitoring. However, it has been noted that SIFs
may have an important role in preventing HCV infection
among PWIDs by serving as an additional mechanism for
the provision of sterile needles in addition to NEPs [64].
Therefore, our results are limited to only one mechanism
of sterile needle access. In addition to sterile needle
provision, SIFs may greatly reduce risky injection practices
(i.e., syringe sharing) that lead to HCV infection [64]. Un-
fortunately, SIFs are not yet widely available in the USA,
in general, and in the rural areas of the USA that are in
the midst of the HCV epidemic, in specific. The very first
SIFs in the USA are preparing to open in 2017 in an urban
location on the West Coast of the USA [65]. Current evi-
dence regarding their impact on HCV seroconversion is
lacking. Hagan et al. [12], upon which we based our search
strategy, failed to find any articles describing the impact of
SIFs or pharmacy sales on HCV seroconversion that met
their inclusion criteria for their systematic review with
meta-analysis. There were 15 studies among the 555 in-
cluded in this systematic review that described SIFs. Only
two of these studies obtained an objective measure (i.e.,
serum or saliva) of HCV infection. However, both studies
were cross-sectional and did not provide data that would
allow calculation of the association between SIF use and
HCV infection. Similarly, and as discussed above, there is
very limited evidence (N = 2 studies) that currently exists
on the impact of pharmacy-based NEP, an area ripe for
further inquiry. Secondly, the current review was unable
to formally assess differential study effects stemming from
different designs using moderator analysis due to the small
sample size. Third, the weaknesses and potential biases in-
herent in individual studies are included in a meta-
analysis, which may have negatively affected this study’s
ability to detect significant results. Such biases include in-
formation bias that could have been present from self-
reports of injection status and NEP attendance, as well as
volunteer bias [66, 67], which represents the phenomenon
of NEP attendance by PWIDs that may be at higher risk
for infectious disease. Fourth, it is possible that studies
were missed during the systematic review and not in-
cluded in the meta-analysis. In addition to not searching
for unpublished sources, the fact that over 100 full text ar-
ticles had to be reviewed to assess inclusion and exclusion
criteria may indicate that studies that address this topic
are not well described in either the title or abstract. Fifth,
a small number of included studies precluded a complete
assessment of the possibility of small study effects, includ-
ing publication bias. Finally, because the aggregate data
approach for this meta-analysis was used, these results are
subject to ecological fallacy [68].
Conclusions
The impact of NEP on the prevention of HCV in PWIDs
remains unclear. Such lack of clarity is likely due to sub-
stantial between-study heterogeneity in study design, inclu-
sion criteria, intervention definition, outcome assessment,
and statistical analyses that yield different pooled results
depending on whether or not a time component (hazard
ratio) is included in the analysis. Studies examining the op-
eration of NEPs in rural areas are particularly needed, along
with research examining the unique barriers to using clean
needles experienced by PWIDs, to clarify the overall contri-
bution of the presence of clean needles in the environment
obtained from NEPs to the successful prevention of new
cases of HCV. Future studies should also examine the im-
pact of other sources of clean needles available for injection,
such as SIFs and pharmacies, on the prevention of HCV
infection in PWIDs. Given the potential benefits of NEP for
reducing infectious disease in a population, future studies
incorporating standardized populations, interventions,
comparisons, outcomes, and analyses are critically
needed to inform public health practice and policy.
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Title: Qualitative Case Study of Needle Exchange Programs for the Prevention of 
Hepatitis C Virus in the Rural Appalachian Region of the United States 
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ABSTRACT 
Background.  The rural Appalachian region of the United States is in the midst of a 
hepatitis C virus epidemic driven by injection of opioids, particularly heroin, with 
contaminated syringes. In response to this epidemic, several needle exchange 
programs (NEP) have opened to provide clean needles and other supplies and services 
to people who inject drugs (PWID). However, no studies have investigated the barriers 
and facilitators to implementing NEPs in rural areas.  
Methods. This qualitative case study consisted of interviews with program directors, 
police chiefs, law enforcement members, and PWIDs affiliated with two NEPs in the 
rural state of West Virginia. Interview transcripts were coded inductively and analyzed 
using NVIVO® software. Final common themes related to barriers and facilitators of 
past program openings, current program operations, and future program plans, were 
derived through a consensus of two data coders. 
Results.  Both NEPs struggled to find existing model programs, but benefited from 
broad community support that facilitated implementation. The largest operational barrier 
was the legal conundrum created by paraphernalia laws that criminalize possession of 
syringes.  However, both PWIDs and law enforcement appreciated the comprehensive 
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services provided by these programs.  Program location and transportation difficulties 
were additional noted barriers.  Future program operations are threatened by funding 
shortages and bans, but necessitated by unexpected program demand. 
Conclusion.  Despite broad community support, program operations are threatened by 
growing volumes, funding shortages, and the federal government’s prohibition on the 
use of funds to purchase needles.  Paraphernalia laws create a legal conundrum in the 
form of criminal sanctions for the possession of needles, which may inadvertently 
promote needle sharing and disease transmission.  Future studies should examine 
additional barriers to using clean needles provided by rural NEPs that may blunt the 
effectiveness of NEPs in preventing disease transmission, and elucidate the factors that 
contribute to geographical funding disparities.   
INTRODUCTION 
 Hepatitis C virus (HCV) is a blood-borne infection that is commonly transmitted 
during injection drug use (Keeshin & Feinberg, 2016; Ward, 2013).  HCV affects an 
estimated 177.5 million (2.5%) of the world’s population (Petruzziello, Marigliano, 
Loquercio, Cozzolino, & Cacciapuoti, 2016), and is the leading cause of advanced liver 
diseases (Cooke et al., 2013; Stepanova & Younossi, 2017).  The worldwide economic 
burden associated with HCV-related liver disease is enormous and includes both direct 
costs related to medical care and indirect costs such as loss of work productivity (Estes 
et al., 2015; Stepanova & Younossi, 2017).  Even in low HCV prevalence (<1%) 
countries such as Iran, HCV economic burden is estimated to eclipse more than $1 
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billion per year (Stepanova & Younossi, 2017; Zare, Fattahi, Sepehrimanesh, & 
Safarpour, 2016).   
Although most countries have seen rates of HCV plateau (Thrift, El-Serag, & 
Kanwal, 2016), incident cases of HCV infection increased more than 2.9 fold in the 
United States between 2010 and 2015 (CDC, 2017).  The majority of these new 
infections have been observed in white, young, people who inject drugs (PWIDs) 
residing in nonurban areas of the United States (CDC, 2017; Havens et al., 2013; Page, 
Morris, Hahn, Maher, & Prins, 2013; Suryaprasad et al., 2014; Ward, 2013; Zibbell et 
al., 2015).  Between 2006 and 2012, the rural, central Appalachian region of the United 
States (Kentucky, Tennessee, Virginia, and West Virginia) observed a 364% increase in 
acute HCV cases in young persons (≤ 30 years old) (Zibbell et al., 2015).  There is 
evidence that this exponential increase is highly correlated with a regional prescription 
opioid abuse epidemic and an increase in injection of illicit street drugs, particularly 
heroin, that occurred during the same time period (Beheshti et al., 2015; Zibbell et al., 
2015; Zibbell et al., 2018).  
The rural state of West Virginia, located entirely in the Appalachian region, has 
the second-highest rate of incident cases of HCV in the country (3.4 per 100,000)(CDC, 
2017) and shares many of the demographic characteristics of PWIDs who are thought 
to be driving the US epidemic (i.e., white and young).  Between 2007 and 2015, the 
HCV incidence rate increased over 300% in West Virginia, and the most frequently 
reported risk factors for developing acute HCV infection were injection drug use and 
used street drugs (WV DHHR, 2017).  In response to this epidemic, needle exchange 
programs (NEPs) began opening in the state during 2015.   
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NEPs exchange used needles for clean needles, and have been shown to 
prevent HCV among PWIDs in several studies (MacArthur et al., 2014).  NEPs are 
recommended by the World Health Organization and other global bodies as a 
mechanism to prevent transmission of infectious diseases including HCV (Csete et al., 
2016). In addition to clean needles, NEPs also provide other injection equipment 
supplies, infectious diseases testing, medical care, and linkage to substance abuse 
treatment (Stancliff, Phillips, Maghsoudi, & Joseph, 2015).  However, in the United 
States, NEPs remain controversial (Csete et al., 2016; Tempalski et al., 2007).  Such 
controversy stems from a historical tendency to treat drug abuse as a moral problem 
that requires a criminal response in the form of arrests and other sanctions (Csete et al., 
2016; Des Jarlais, 2017; Vlahov et al., 2001).  Furthermore, some members of the 
public have voiced concern that NEPs amount to explicit encouragement and support of 
destructive drug use (Vlahov et al., 2001). Consequently, public policies have limited the 
coverage and effectiveness of NEPs (Csete et al., 2016; Des Jarlais, 2017) in the urban 
areas where they historically operated.   
Despite the clear need for NEPs in rural states like West Virginia, there remains 
a dearth of research documenting the unique context and challenges to operating NEPs 
in rural areas that can provide critical information on the barriers and facilitators that 
impact overall program effectiveness (Davis et al., 2017).   A mail/telephone survey with 
the directors of NEPs operating in the United States in 2013 revealed that rural 
programs were more likely to report experiencing a lack of resources/funding compared 
to suburban and urban programs (73% versus 64% and 63%, respectively) (Des Jarlais 
et al., 2015).  Rural programs were also slightly more likely to report experiencing 
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problems reaching or recruiting participants compared to urban programs (20% versus 
18%, respectively).  However, challenges and barriers related to program design, 
implementation, and sustainability were not reported. Therefore, the purpose of this 
study was to conduct a qualitative case study of two NEPs that opened in West Virginia 
in 2015.  As part of this case study, we compared and contrasted the experiences and 
contexts of each program to identify common themes related to program operations. Of 
specific interest were the facilitators and barriers to the implementation and ongoing 
operations of each program. In particular, this case study sought to answer the following 
questions: (1) What were the facilitators and barriers to opening the program?; (2) What 
were the facilitators and barriers encountered during the day-to-day running of the 
program?; (3) What were the future plans for the program?; and, (4) What were the 
challenges and barriers related to these future plans?   
METHODS 
Approach 
A multiple, intrinsic case study approach was selected for the following reasons:  
1) each case (NEP) was of interest in and of itself (i.e., intrinsic) (Stake, 1995); 2) the 
goal of this study was to obtain an in-depth understanding of each case (Creswell, 
2013); and, 3) each program (case) was a bounded system (Creswell, 2013). For the 
purposes of this study, we bounded each case to the specific program, and examined 
the past, present, and future time orientations of each program. Although no specific 
time limits were placed on each orientation, all information gathered was focused on 
facilitators and barriers encountered by (or expected to be encountered by) the program 




Each case was selected using a purposive sampling strategy (Miles, 1994). West 
Virginia currently has 10 NEPs registered with the North American Syringe Exchange 
Network (North American Syringe Exchange Network, 2018). For this study, we 
purposefully selected two of the longest operating programs, a NEP operating within a 
free healthcare clinic and a NEP operating within a health department, to glean 
important insights from their significant experiences and document variations between 
the two program structures.     
Data collection 
To answer the central research questions, the lead author (SD) conducted in-
depth interviews with the director of each program.  At one site, other administrative 
personnel (i.e., the nursing director and site administrator) also participated in the 
interview.  In-depth interviews were selected to obtain a deeper understanding of these 
novel programs that arose in response to a desperate situation. In the interest of 
triangulating data to develop emergent themes, police chiefs and other law enforcement 
officers in the areas served by the programs, as well as the NEP attendees currently 
using each program, were interviewed.  Director interviews occurred in March 2016, law 
enforcement interviews occurred during the summer of 2016, and interviews with 
program attendees occurred during the summer of 2017. 
Prior to conducting each interview, a semi-structured interview guide was 
developed. The structure of the interview guide was focused on the facilitators and 
barriers encountered during the past and present, as well as those anticipated to occur 
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in the future. However, due to the interest in obtaining an in-depth understanding of the 
central research questions from the viewpoint of respondents, each interview was semi-
structured, and conversations were allowed to emerge and flow in naturalistic directions 
that may have departed from the interview guide.  This approach is consistent with a 
social constructivist framework (Denzin, 2011).  Importantly, the specific questions 
included in the interview guide were also guided by initial discussions with each director 
and included questions of interest to him or her.  Finally, a case study of the first NEP in 
the United States, Point Defiance (Sherman & Purchase, 2001), was also used as a 
source of potential questions.  
Prior to starting the interview, interviewees were informed that the discussion 
was voluntary and could be ended at any time without penalty.  Interviewees were also 
informed that all discussions were confidential and that the specific program would not 
be identified in any publications or presentations.  Therefore, each case has been 
assigned a pseudonym (Free Clinic NEP and Health Department NEP).   
Each interview took place in a private conference room or via telephone and 
lasted approximately 60 minutes.  Interviews were recorded using a TasCAM DR-05® 
stereo handheld microSD (TASCAM, 2016).  As a backup measure, interviews were 
also recorded using Apple® iPhone’s Voice Memos utility (Macworld, 2016).  At various 
points throughout each interview, the interviewer summarized the discussion and 






Interviews were transcribed by a professional and entered into NIVIO® 11 Pro 
software for analysis (NVIVO, 2016).  Prior to formal analysis, each transcript was read 
several times and notes were made regarding initial codes and categories. The initial 
codebook had a priori codes for past, present, and future, in which information on 
barriers and facilitators corresponding to each time period was categorized. However, 
no other codes were assigned a priori, and line by line coding was conducted with the 
objective of identifying approximately 5 to 7 general themes in the interest of parsimony.  
In the constructivist tradition, codes were allowed to emerge from the data prior to 
categorization into themes (Denzin, 2011).  This approach allowed for the discovery of 
information that was surprising and not expected.  As suggested by Yin, a cross case 
synthesis was conducted to denote similarities, differences, and emerging themes 
between the two cases (Yin, 2016).  
After initial coding and classification, intensive group discussion with a second 
coder with expertise in qualitative research (DD) with a goal of simple consensus was  
employed to finalize the codes and overall themes (Brinkmann, 2015; Harry, 2005; 
Sandelowski, 2007).  If needed, discrepancies were resolved by a third party.  This 
approach is recommended by several methodologists in order to preserve the 
interpretive process at the core of qualitative analysis (Saldana, 2016), and is consistent 
with current case study practice (Atchan, Davis, & Foureur, 2016), in specific, and 
generally accepted qualitative research reporting criteria (Tong, Sainsbury, & Craig, 
2007).  Themes were classified according to time orientation (i.e., past, present, future) 
and whether it reflected a barrier or facilitator to program operations.  Respondent 
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quotes that captured the essence of each theme were selected as the primary data 
outcomes.  Findings and interpretations of the data were shared with interviewees (i.e., 
member checking) to assess the accuracy (validity) of the measurement, and 
naturalistic generalizations were made by comparing emergent themes with previously 
published literature (Creswell, 2013).  This protocol was approved by the referent 
university’s Institutional Review Board.   
FINDINGS 
Sample Characteristics 
Qualitative interviews were conducted with two program directors, a program 
administrator, a program nurse, two chiefs of police, two law enforcement officers, and 
eight PWIDs (4 male, 4 female) who attended the two programs.  
Description of Cases 
Free Clinic NEP 
The Free Clinic was founded in 1984 by a group of concerned citizens on the 
premise that healthcare is a universal right that should be available to all citizens 
regardless of ability to pay.  In response to an ever-growing need, the clinic has moved 
several times, occupying larger quarters each time, and currently occupies a two-story 
building with ten exam rooms, two waiting rooms, a medication room, conference 
rooms, offices, and storage areas.  The agency has a staff of 21, a volunteer corps of 
more than 200, and provides more than 28,000 patient encounters and dispenses free 
medications in the millions to qualified patients every year.  In addition to medication 
assistance, the Free Clinic provides primary health care with a professional staff of 
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physicians, nurse practitioners, physician assistants, registered nurses (RNs), licensed 
practical nurses (LPNs), medical assistants, social workers, and therapists. Specialty 
clinics for various diseases (e.g., diabetes) and topics (e.g., women’s health) are also 
offered.  Some dental care and mental health services are provided on a limited basis.  
It is supported by the United Way, as well as various federal, state, and local grants, but 
also greatly depends on donations and in-kind gifts from individuals.  All health care, 
including prevention, health awareness, and chronic disease management, are free of 
charge to qualified patients and are offered in clinics or in group education. 
Precipitating Event/Program Impetus 
Although Free Clinic personnel were aware that some patients were also 
injection drug users, the significant incidence of HCV among this population was not 
discovered until the Centers for Disease Control (CDC) updated its HCV screening 
guidelines to recommend testing for all persons between 45 and 64 years of age (Smith 
et al., 2012).  The Free Clinic began implementation of the updated guidelines in June 
2013, and within one month, slightly over 10% of 300 patients tested positive for HCV.  
This event led to an examination of factors related to the high HCV rate, which revealed 
that most of the HCV positive individuals either had a history of injection drug use or 
were currently injecting.  Around the same time, clinic personnel became aware of a 
heroin epidemic in West Virginia that emerged from an opioid abuse epidemic (Beheshti 
et al., 2015). Collectively, these two factors led to the further exploration of a NEP to 
prevent new HCV infections.  Between July 2013 and October 2014, the Free Clinic 
conducted in-depth research regarding the startup and implementation of NEPs, and 
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presented this information to the Board of Directors at the October meeting in 2014. The 
board unanimously approved (20-0) the implementation of a NEP, which led to a quest 
to secure funding and logistical planning related to implementation.  After obtaining 
support from the board to open a NEP, the Free Clinic NEP established a Community 
Advisory Board (CAB) comprised of members of the community, a representative of the 
police department, and a social worker.  The CAB also sought information from current 
users to guide the decision-making process.  The Free Clinic NEP officially opened on 
August 19, 2015 and treated two clients the first day. 
Program Operations 
The Free Clinic NEP is open between 3:30 PM and 6:30 PM every Wednesday, 
and makes special arrangements for attendees who cannot attend on Wednesdays. 
During this time period, no other clinic services are provided.  There are three staff 
members that are dedicated to the NEP, and students from a nearby university also 
assist with operations.  PWIDs of all ages are accepted with a very specialized protocol 
for those under 18 years of age, although no children had yet been seen at the time of 
the interview. The average age of attendees is 33 (range 19 – 70) with slightly more 
males than females (60% versus 40%, respectively).  All but 3% of attendees are 
Caucasian.  Each attendee is assigned a unique identification number for tracking 
purposes during the initial intake.  Basic information regarding injection history, 
including duration and drug of choice, is also collected at this time.  Clients are queried 
regarding whether or not they know their human immunodeficiency virus (HIV) and HCV 
status, and testing is encouraged.  Importantly, all data collected in the context of the 
NEP is kept entirely separate from clinic medical records.  The program operates year-
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round.  At the time of data collection, 200 unduplicated patients had attended the 
exchange since its opening.   
Each attendee leaves with approximately 30 to 50 clean needles.  Additional 
drug paraphernalia, including cookers, cotton balls, alcohol swabs, and tourniquets, are 
also provided.  The exchange offers rapid HCV testing as well as serum HIV testing.  
Attendees also have access to a social worker and a nurse practitioner to discuss any 
health-related issues.  Discussions regarding harm reduction, healthcare, treatment, 
housing, and general case management are common. 
Health Department NEP 
 The Health Department NEP is located within a public health agency that 
provides a plethora of environmental and epidemiological public health services 
including environmental services (e.g., food safety, etc.), clinic services (e.g., sexually 
transmitted infection (STI) clinics, immunizations, etc.), threat preparedness, and 
disease investigation. 
Precipitating Event/Program Impetus 
In November 2014, a local Office of Drug Control Policy was created by the 
mayor of the town in which the health department is located.  An investigation by this 
office into the problem of drug use found an extremely high rate of drug overdose, 
primarily from heroin.  However, most concerning was the observed rising death rate:   
We had a very, very, very high rate of overdose and what was happening that grabbed our 
attention was our death rate.  Our death rate was beginning to balloon.  I don’t remember the 
exact numbers but we had somewhere in the neighborhood of 15 deaths in January and February 




During this same time period in 2015, Scott County, Indiana was in the midst of 
an HIV epidemic from injection of illegal drugs with contaminated needles that led to the 
opening of a NEP to combat the epidemic (Strathdee & Beyrer, 2015).  These two 
factors led to the decision to explore the implementation of a NEP in this local West 
Virginia community. After extensive research on other NEPs (including visits to a small 
rural community in a neighboring state between January and April 2015), obtaining legal 
clearance, and the acquisition of adequate funding, the Health Department NEP 
formally opened on September 2, 2015.  At the time of data collection, the NEP had 
seen 977 unique clients and exchanged 2,500 needles since its opening. 
                         Program Operations 
The Health Department NEP runs three exchange rooms on Wednesdays during 
a five hour period. In contrast to the Free Health Clinic NEP, other health department 
services are also offered during the same time period.  Approximately 15 individuals 
comprised of seven staff members, pharmacy, nursing, and medical students, and 
recovery coaches are present during operating hours.  On any given Wednesday, 
approximately 130 attendees use the exchange with a single day high-volume of 144 
attendees observed.  Attendees receive a maximum of 40 clean needles, and most 
attendees bring in approximately 30 to 40 used needles to exchange.  In addition to 
exchanging needles, the Health Department NEP provides recovery coaches, STI 
testing, as well as testing for HCV (serum) and HIV.  Attendees are also queried 
regarding their infectious disease status, and are provided access to nurses who can 
examine their injection sites for potential infection.  Teaching regarding safe and clean 
injection is also provided, and attendees with infected sites are seen by a nurse 
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practitioner.  The administrative staff described difficulties related to the fact that routine 
health department services are offered during the times that the NEP is open.  For 
example, many of the NEP attendees were smokers who were frequently going outside 
to smoke, which disrupted other health department clientele. 
Attendees of the Health Department NEP are heterogeneous and contain a 
range of individuals from functioning addicts that are gainfully employed despite 
addiction to one or more substances to the more stereotypical drug addict (e.g., 
unemployed, homeless, etc.).  Although identification is not required by the Health 
Department NEP, the created ID number assigned to each participant for tracking 
purposes includes birth year.  Gender is split evenly, and 96% of attendees are 
Caucasian, which is similar to West Virginia as a whole (94% Caucasian) (U.S. Census 
Bureau, 2017). The average age is 37 and ranges from 21 to the 60s.  
Past Barriers and Facilitators to Opening the Program 
 
One Size Doesn’t Fit All  
 
The theme, One Size Doesn’t Fit All, was identified from NEP directors’ 
descriptions of difficulties (i.e., barriers) encountered with locating an existing exchange 
program to serve as a model for the development of a NEP in their rural communities.   
 The Free Clinic NEP enlisted the support of students from a nearby university to 
conduct research on the existence of comparable exchange programs to no avail.  This 
absence of model programs led to the need to modify elements of existing program 
policies from states such as New York to include policies for dealing with underage 




So we did a lot of research and we found out that in some cities like Baltimore there’s a syringe 
exchange on almost every corner at different times during the week.  But we didn’t find any 
information about small town USA.  And I’ve also been involved in outreach in [another rural 
community] and have just recently did a conference call with several smaller communities.  That’s 
the key here.  The smaller communities are trying to break into this but the only model that’s out 
there is really for more urban areas. (Director)   
 
Similarly, although the Health Department NEP was able to visit a program that was 
implemented in a nearby small community of approximately 5,000 residents, this 
program only exchanged needles and provided pamphlets with information, as opposed 
to the more comprehensive program models that include a variety of health services 
offered in other, more urban settings. Some NEP policies and procedures information 
was located on the Web, but the Health Department did not have the luxury of time to 
refine policies and procedures prior to program operations due to exponential program 
demand, which is further discussed below.  
Like a Good Neighbor  
The theme, Like a Good Neighbor, included participant descriptions of the 
facilitative role that support from the community played in both program implementation 
and the ability to sustain the program moving forward (discussed below). Despite 
difficulties related to finding model programs during program development, both 
program openings were significantly facilitated by support from the community, albeit in 
somewhat different ways.   
The Free Clinic was initially concerned about a potential absence of community 
support and choose a silent opening that did not involve media announcements. 
However, once such announcements were made, the result was an overwhelming level 
of support:  
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So we did a very quiet start.  We did not publicize. . . . . we knew that this would generate 
emotional feelings and thoughts and that we hoped people would call and ask questions and try 
their best to understand. The response was 14,000 dollars, and we did not ask for money. 
In contrast, the Health Department NEP enjoyed broad community support due 
to concern over the overwhelming number of opioid overdose deaths: 
. . . [A] community meeting happened in March through a local, I don’t know what you call her, 
just a local community member that was interested and 500 people attended that. . . .This was 
organized as a Facebook campaign by a community person.  This was not organized by any 
official.  They got the room at the library and there were 500 people up there and it was testimony 
after testimony from families who had lost people from people who are recovered from this 
addiction.  And there was uniform support.  And in fact it went beyond the uniform support for the 
effort to the question, “Why are you not doing this?” (Administrator) 
 
However, as discussed below, having a continuous supply of clean syringes was 
identified as a shared barrier to future operations. 
Present Barriers and Facilitators to Operating the Program 
The Legal Conundrum 
The theme, The Legal Conundrum, was identified from participant discussions of 
the impact of paraphernalia laws and policing behaviors on program operations and 
participation.  Both programs cited the critical importance of law enforcement support to 
successful program implementation and operations.  However, existing paraphernalia 
laws and the fact that injection of illicit substances is an illegal activity created a 
quandary for law enforcement officials regarding the best approach to the possession of 
drug paraphernalia that may threaten the harm reduction goal of the NEPs:  
So the police officer who participates got permission from the chief of police to participate and 
then we, our medical director and myself went over and had a face to face meeting with our city 
police chief because we felt like we needed them on our side. . . .we didn’t want to get to a point 
where we were giving out syringes, they would arrest somebody, confiscate those syringes and 




Law enforcement leadership provided significant support for the programs and proffered 
directives to not seize clean needles in certain circumstances: 
What my instructions have been is if you catch somebody coming out of [the NEP] with a bag of 
clean needles, or somebody that comes out of a pharmacy, that’s not really drug paraphernalia.  
It’s got to be in conjunction with you know you’ve got the spoon, you’ve got the tie off, you know 
it’s clear that that’s what they’re using it for.  (Police Chief)  
 
However, despite this crucial support, variations in the particular actions taken in the 
case of clean (unused) needles were recorded.  For example, one law enforcement 
officer advised NEP attendees to not call attention to themselves by engaging in 
suspicious or criminal activity that may lead to the discovery of syringes and possible 
citation or arrest: 
It’s still drug paraphernalia…If you’re stopped by law enforcement, it’s not an exemption because 
you’re not supposed to be out here walking the streets carrying your drug paraphernalia and that 
kind of stuff.  You know like I said they know what they’re dealing with and they know the actual 
laws for the use of. Yeah, don’t draw attention to yourself and then you might get by.  
 
Other officers felt that giving citations for syringes would be a mechanism for linking 
attendees to treatment via a law enforcement diversion program whereby attendees 
would be sent to court-ordered treatment instead of jail.  Attendees reported receiving 
legal sanctions for having clean needles obtained at the exchange despite showing 
proof (i.e., NEP identification card) when being stopped or searched for other reasons:  
 




These experiences created confusion among NEP attendees who believed that clean 




They tell you when you first start with the card that it's a one way trip. You got from the exchange 
to your home and from that point on you're not covered by that card with the needles, only from 
here to home. It's supposed to be a straight shot and the first time I ever came they explained 
that to me in full detail that you have a one way trip with them [the police]. 
 
Another attendee stated: 
 
They give you a card and I got pulled over and I showed them that card and they said that, that 
didn't matter at all. All that did was show where I got them from, that it was still paraphernalia and 
that it was still a misdemeanor. 
 
One attendee described an encounter with a law enforcement officer that felt the NEP 
itself should be illegal: 
I came across a policeman, and he was searching my stuff because I was around someone on 
house arrest. He was into my stuff. He seen my card from the [NEP]. He was like, "This is illegal. 
I know why you go there. This is illegal." I'm like, "No, it's not. It's not illegal to go there and get 
syringes." He's like, "Yes, it is, and I'm going to make sure they close down."  
 
Location Is Everything 
The theme, Location Is Everything, was identified from participant discussions of 
difficulties related to program utilization stemming from the physical location of the 
exchanges.  One NEP was located very near to the police department, which was 
acknowledged by all parties interviewed to “absolutely suck.”  The other NEP was 
perceived as being too far away to promote regular attendance by attendees in the 
surrounding community. The Free Clinic NEP has some attendees that come from a 
rural county that is a two hour drive one way due to the absence of such programs in 
the local community, and the Health Department NEP expressed an interest in 
expanding to an adjacent area where the death rate is high but distance precludes 
attendance by some users.  One attendee mentioned driving one hour, one way to 
obtain injection equipment, which precluded frequent and regular exchange attendance.  
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All participants agreed on the need for expanded NEP services at other locations to 
reach more users.   At the time of this writing, the Free Clinic NEP obtained funding to 
purchase a van for a mobile NEP, and several other NEPs have opened throughout 
West Virginia with plans for additional programs pending. 
Harm Reduction for All 
The theme, Harm Reduction for All, included discussions of how the NEP could 
positively reduce the spread of disease for all participants (i.e., law enforcement, 
attendees, and the surrounding community).   
Law Enforcement 
Law enforcement support for NEPs was facilitated when the intervention was 
viewed as an effort to reduce harmful blood borne pathogens that could be contracted 
by a needle stick occurring during subject searches:    
Well myself personally you know I’ve got a family.  You know I don’t want to be out here and you 
know being on the front line dealing with these addicts you know.   I don’t want to be stuck with a 
dirty needle.  I’ve been stuck with a dirty needle before and it’s not very pleasant the treatment 
that you have to go through.  
 
Attendees 
NEP attendance was facilitated by attendees’ concern with the prevention of 
abscesses and other blood-borne infections, especially HIV, and most felt that NEPs 
saved lives:  
It's a life changer, really. It's a life changer that you can come up here once or twice a week and 
get what you need other than going and trying to go and find it [needles] on the street. It's saving 




However, concern over contraction of HCV was mitigated by the perception that 
it is an inevitable byproduct of intravenous drug use that all drug users eventually 
acquire:   
It's like, I wear a pair of Levis you know, that's what it's like.  
 
HCV concerns were also blunted by the fact that many users remain asymptomatic for 
years: 
…You got all these people walking around, well I got Hep and you're looking at them you're like 
aw they're fine. I mean the long term effects obviously are [bad].  
 
One attendee mentioned that he would feel uncomfortable injecting with an individual 
who claimed he or she was HCV negative, stating that such an individual might be a 
member of law enforcement engaged in an undercover sting operation.  
For attendees, the fact that these programs are built on the social work principle 
of meeting people where they currently are in their addiction and keeping them safe that 
underlies the harm reduction approach, was central to facilitating attendance (Vakharia 
& Little, 2017). In particular, the nonjudgmental, welcoming attitude espoused by all 
program staff was instrumental to encouraging attendance: 
Even the woman at the front desk here….she's smiling.  
No judgment. Oh yeah that's a big [facilitator], that's your first impression. 
 
Another attendee stated: 
 
The fact that you can come here, and you can get a one-week or a two-week supply. You're not 
turning people down because of their race, color, or gender. You are welcoming anybody. It's 










 Attendees were particularly concerned with discarded needles and noted the 
positive benefit of biohazard receptacles that are given to attendees at one NEP for 
needle disposal: 
Well, I think another thing is when everybody gets rid of them, like that actually does come here 
and get them, they actually throw them away the right way. Don't throw them out the fucking 
window or anything like that because that's where "junkie" comes from.  
 
Attendees of the other exchange requested that more biohazard containers be 
made available to reduce dirty discarded needles in the community.  Additionally, the 
Health Department NEP created an environmental response team and engaged in 
community education. Community members are able to call the response team to come 
and safely removes needles found in the community. 
Not Just A Needle 
The theme, Not Just a Needle, included instances where participants described 
the importance of other supplies and services in addition to clean needles provided by 
the exchanges.  Attendees appreciated the other comprehensive services provided, 
such as infectious disease testing and medical care, and linkage to drug treatment was 
a very important facilitator of program acceptance among law enforcement.  
The chiefs of police described the importance of the exchanges as a blood-borne 
pathogen intervention with a “gateway to recovery” as opposed to a mere harm 




But then you also have that real fine line.  Are you encouraging the continued use of an illegal 
controlled substance or are you treating it?  And I think the panacea is there are two different 
things.  You’re trying to intervene on the [blood borne] pathogens.  And through that blood borne 
pathogen intervention you’re trying to reach out to change the thought processes of the illicit drug 
user.  And I think that’s where people lose the message here that it’s not one you know feeding 
the other.  It’s one or the other, because that’s what you have.  The needle exchange is a blood 
born pathogen intervention not a drug intervention.  But they’re trying to pull the drug intervention 
in by getting a hold of them through the medical intervention. (Police Chief) 
 
Future barriers and facilitators to expanding program operations 
 
Surging Volumes:  The Storm Before The Calm  
The theme, The Storm Before the Calm, was identified from discussions of unexpected 
demand for exchange services that created additional barriers to program operations 
and participation.  This demand for the NEPs was greatly underestimated by both 
programs: 
Well we anticipated only having 75 clients in the first year, which was my naïve thinking I guess, 
our belief that the situation wasn’t as bad as it really is.  And it was also based on thinking that 
most of these folks would be people we knew. (Free Clinic NEP Director) 
          
 
We initially planned for about 500 participants for a year.  So September 16 [2016] we expected 
to be at 500.  We were at 500 in about nine weeks.  So we immediately knew that we made a 
small error in judgment. (Health Department NEP Director) 
          
 This overwhelming demand, coupled with the previously discussed location and 
access problems, have led to plans for future expansion by both programs to help calm 
the storm of attendees. The Free Clinic NEP would like to expand services to more rural 
counties via a mobile van that was recently purchased; whereas, the Health Department 
NEP has plans to expand from the current single site to four sites.  
Attendees also cited the need for expanded hours of operations: 
. . . what we put in these don't come through no schedule. One things for certain in the dope 
game, nothing's for certain. . . .It's difficult. . .Some people can't come on a Wednesday. Some 
people can't come here all the time. 
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However, common to both programs was a shortage of available funding, which 
significantly threatens the ability to expand: 
We can see that we need to expand this, that we are overwhelmed by the volume of patients that 
we’re seeing. . . .But we don’t have funding to go on with that.  And we don’t have sustaining 
funding beyond the first year when you get right down to it. (NEP Director) 
 
Could You Spare Some “Change”? 
The final theme, Could You Spare Some “Change”? was derived from codes assigned 
to participant discussions of funding barriers related to a federal ban on funding of 
exchange programs.   Although this ban was recently lifted (“changed”), and federal 
dollars can now be used to fund program operations, both programs have to rely on 
other sources to fund syringes. The Free Clinic NEP primarily uses money from 
foundation grants and donors to pay for syringes and other paraphernalia; whereas, the 
Health Department NEP relied on donations from a local pharmacy of between 13,000 
and 15,000 syringes, and another large donor who contributed 60,000 syringes. For 
both programs, this barrier limits the number of syringes that can be distributed, which 
can negatively impact the secondary exchange of syringes that occurs when an 
attendee takes clean needles and distributes them to other PWIDs in the community.  
To combat significant funding pressures, both programs cited the ability to 
leverage resources from nearby universities (Like a Good Neighbor theme), or as one 
Health Department NEP representative said, “Thank goodness for the students.” 
University affiliated medical and pharmacy professionals also donate their time to each 
program, which greatly helps offset funding challenges.  However, the survival of each 
program is contingent on the continued support of the surrounding community and 
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community champions, particularly law enforcement leadership, given the legal 
conundrum created by existing policy and laws.   
DISCUSSION 
This case study of two needle exchange programs that opened in West Virginia 
in 2015 reveals common barriers and facilitators that impacted program implementation, 
operations, and future planning. At the outset, both programs struggled to find existing 
programs to effectively serve as a model.  Although each program had slightly different 
precipitating events that drove the need for such programs in each community, both 
observed attendance rates far greater than anticipated, and have faced significant 
funding challenges that impacts future expansion needs driven by increasing volumes 
and significant transportation barriers to program attendance. The legal conundrum 
created by legal distribution of clean needles in the presence of paraphernalia laws 
rooted in a criminal (i.e., moral) approach to drug use that impacts policing behaviors 
was a noted barrier to program operations. Despite these challenges, robust community 
support and the creative leveraging of volunteer resources have facilitated the 
successful implementation and operation of these programs.  
In-depth case studies describing the development and implementation of NEPs 
in the United States are scant. The literature largely consists of brief descriptions of the 
first NEPs to open in urban areas of the United States (e.g., Tacoma, San Francisco,  
New York City, Washington, DC, etc.) in the late 1980s and early 1990s in response to 
the HIV crisis (Anderson, 1991; Hagan, Des Jarlais, Purchase, Reid, & Friedman, 1991; 
Kaplan & O'Keefe, 1993; Sherman & Purchase, 2001; Somlai, Kelly, Otto-Salaj, & 
Nelson, 1999; Vlahov et al., 1994; Watters, Estilo, Clark, & Lorvick, 1994),   Only two 
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studies (Sherman & Purchase, 2001; Somlai et al., 1999) were located that specifically 
described the use of qualitative research methodologies to obtain an in-depth program 
(i.e., case) understanding. However, these differences notwithstanding, there were a 
number of similarities with regard to barriers and facilitators experienced by these urban 
programs and the two West Virginia exchanges that comprise this case study.  
First, as was experienced by both West Virginia programs, there was no readily 
available model exchange in the United States to guide program design and 
implementation (One Size Doesn’t Fit All theme). Rather, many urban programs used 
the first NEPs that opened in Amsterdam as a guide to program development 
(Anderson, 1991; Hagan et al., 1991; Kaplan & O'Keefe, 1993; Sherman & Purchase, 
2001). Other programs engaged the surrounding community during program design and 
implementation (Kaplan & O'Keefe, 1993; Somlai et al., 1999).  For example, the 
Lifepoint NEP case study described the use of qualitative ethnographic methods and 
systemic community analysis in the design and implementation of a NEP in Milwaukee, 
Wisconsin (Somlai et al., 1999), which is similar to the community advisory board and 
key informants used to guide the development of the Free Clinic NEP.  Program 
planners also engaged community leaders and law enforcement in the design and 
implementation of a NEP in New Haven, Connecticut (Kaplan & O'Keefe, 1993).    
Community support was cited as critical to program implementation and 
continuing operations by a few studies (Kaplan & O'Keefe, 1993; Sherman & Purchase, 
2001; Somlai et al., 1999), especially support from community leaders such as the chief 
of police, the mayor, and the health department director (Like a Good Neighbor theme). 
In particular, the initial support of the health department was cited several times 
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throughout the Point Defiance NEP case study in Tacoma, Washington (Sherman & 
Purchase, 2001) as a prominent factor in the successful implementation and ongoing 
operation of the exchange, and has been critical to the success of the Health 
Department NEP in this case study. Although both programs in our case study enjoyed 
broad support from the chiefs of police, support among rank-and-file officers was 
somewhat divided, which likely contributed to the negative experiences with law 
enforcement shared by the attendees interviewed.  To promote police acceptance of the 
NEP, program leaders of the LifePoint NEP involved law enforcement in the planning 
process, as did both of the West Virginia programs in this case study. Although no 
attendees reported police harassment after the LifePoint NEP implementation, the 
overall attitude of law enforcement with regard to the program remained largely neutral 
(Somlai et al., 1999).   
Most urban programs have also described difficulties stemming from the 
existence of paraphernalia laws and associated policing behavior (The Legal 
Conundrum theme) (Hagan et al., 1991; Kaplan & O'Keefe, 1993; Vlahov et al., 1994). 
The Point Defiance NEP did not experience many operational barriers, at least initially, 
primarily because the chief of police made a conscious decision to not arrest the 
founder for violation of state paraphernalia laws.  Additionally, the state Supreme Court 
later ruled in favor of the exchange finding that public health interests superseded 
existing drug paraphernalia laws (Sherman & Purchase, 2001).  However, it is unknown 
whether or not rank-and-file law enforcement officers also chose to ignore paraphernalia 
laws in their dealings with PWIDs, which was a noted barrier reported by attendees in 
our setting.  
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Funding was a major barrier cited by both West Virginia programs that impacted 
both current operations and needed expansion plans (Could You Spare Some “Change” 
theme). A notable exception to this case is the Point Defiance NEP in Tacoma, 
Washington where community support minimized financial barriers. Funding from 
private citizens, in addition to city and county sources, were cited as contributing factors 
to a program budget that continued to grow (Sherman & Purchase, 2001). Similarly, the 
LifePoint NEP case did not report funding difficulties (Somlai et al., 1999). However, 
funding difficulties have been reported more recently by NEPs in the United States 
regardless of geographical location, although more rural programs reported funding 
difficulties in comparison to their urban and suburban counterparts (Des Jarlais et al., 
2015).   
NEP funding difficulties were exacerbated by exponential growth that 
necessitated the need for geographic expansion (The Storm Before the Calm and 
Location Is Everything themes).  This expansion involved delivery of needles to 
attendees who did not or could not attend the original fixed site location, which is similar 
to the expansion plans of the Free Clinic NEP (i.e., van delivery of supplies to an 
adjacent county) in this case study, and another study in which NEP attendees listed 
inconvenient location/hours as a barrier to exchange participation (Rich, Strong, Towe, 
& McKenzie, 1999).  Other urban programs have also cited the benefits from using a 
mobile versus fixed site program model to reach more PWIDs (Kaplan & O'Keefe, 1993; 
Somlai et al., 1999).  
Although NEPs provide all supplies needed for the injection process due to the 
belief that HCV can be present in more than the needle, a very recent study has cast 
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doubt on the utility of this approach. Experiments were designed to replicate drug 
sharing practices, but no HCV could be recovered from the cookers.  Furthermore, HCV 
was only recovered in 15.4% of detachable filters and 1.4% of fixed filters (Heimer et al., 
2017).  Although additional research is necessary to replicate this preliminary study, the 
authors conclude that NEPs faced with financial difficulties may consider focusing 
resources on the syringes themselves versus the additional injection equipment.  
NEP funding has historically been inextricably intertwined with paraphernalia 
laws in the United States (Golding, 2017).  In a recent analysis of the 
comprehensiveness of state laws to prevent HCV (Campbell et al., 2017), West Virginia 
was one of 18 states with the least comprehensive laws.  These states had no 
authorization of statewide syringe exchange, no laws decriminalizing possession and 
distribution of syringes, and no laws explicitly allowing the retail sales of syringes 
without a prescription. The absence of explicit direction from the state may have 
contributed to differing practices among law enforcement officers related to whether or 
not attendees should be legally sanctioned if found to be in possession of syringes, 
either dirty or clean.  
 Law enforcement attitudes toward PWIDs may also impact the approach to drug 
paraphernalia. Although the law enforcement officials participating in this case study 
were generally supportive of NEPs, many acknowledged that their fellow officers may 
share divergent views (i.e., in favor of a criminal approach to drug paraphernalia), and 
the experiences of NEP attendees highlighted this diversity of opinions.  A qualitative 
study of the NEP barriers to implementation conducted in China observed similar 
results. As was the case in our study, law-enforcement officials in China tended to view 
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NEP as a temporary measure in place of legal sanctions, and some viewed these 
programs as an explicit encouragement of drug use (Koo et al., 2015).  
Recent evidence has suggested a link between syringe sharing and police 
confiscation of needles, both clean and used.  A cross-sectional survey of IDUs in 
Tijuana and Ciudad Juarez, Mexico observed increased odds of receptive syringe 
sharing from arrests for possessing both clean needles (aOR 2.05, 95% CI, 1.26, 3.35) 
and used needles (aOR 2.87, 95% CI, 1.76, 4.69) (Pollini et al., 2008).  These findings 
are particularly concerning given the fact that syringe sharing is associated with a 94% 
increased risk of acquiring HCV (Pouget, Hagan, & Des Jarlais, 2012).  However, the 
impact of these paraphernalia laws and policing behaviors on the ability of PWIDs to 
both bring clean needles back for exchange and have clean needles available for use 
during injection in a rural area is currently unknown and warrants further inquiry.  
Limitations  
Some study limitations should be noted. It is possible that responses may have 
been impacted by social desirability bias given the sensitive topic. However, no names 
or demographic information were collected or reported to help minimize the impact of 
this bias and increase the validity of the measurement. Additionally, the experiences of 
other rural programs in both West Virginia and other locales may be somewhat different 
than the experiences described in this case study given that the small sample size may 






The primary author’s social work background and experience with individuals 
suffering from addiction could have affected the interpretation of the results and led to a 
positive evaluation of many aspects of the program.  
CONCLUSIONS  
Due to overwhelming need, PWIDs are often in the dark regarding the precise 
outcomes that will be experienced during their next injection.  Will it be the sought-after 
high or a disappointing low?  Will it be a fatal overdose or a ‘near-miss’?  Similarly, the 
two West Virginia needle exchange programs described in this case study have been 
forced to take a shot in the dark and open NEPs in the absence of model programs, 
adequate funding, and other resources, due to overwhelming need in their small 
communities.  Despite these challenges, such programs have enjoyed robust 
community support, and have creatively navigated unexpected problems and 
challenges to effectively implement needle exchange programs in their rural 
communities.  However, surging attendee volumes amidst ongoing funding challenges 
coupled with location and transportation barriers make the future trajectory of such 
programs difficult to predict.  Additionally, the efficacy of these programs in preventing 
transmission of blood borne viruses may be compromised from the legal conundrums 
created by paraphernalia laws and policing behaviors that may promote needle sharing 
that is the primary risk for acquiring HCV among injection drug users. Future studies 
should investigate these potential barriers to using clean needles in rural injection drug 
users. Studies elucidating factors contributing to the funding disparity experienced by 
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ABSTRACT 
Background and Aims.  Using a new (clean) needle for every injection can reduce the 
spread of infectious disease among people who inject drugs (PWID).  However, barriers 
to using clean needles are not well understood, and no previous study has examined 
these barriers among PWIDs residing in the rural Appalachian part of the United States, 
an area currently in the midst of a heroin epidemic.  Therefore, our primary aim was to 
explore self-reported barriers to using a clean needle by PWIDs attending a needle 
exchange program (NEP).  Design and Setting.  We conducted a cross-sectional 
survey of PWIDs attending two NEPs in rural West Virginia located in the heart of 
Central Appalachia.  Measurement.  A convenience sample of PWIDs (n = 100) 
completed the Barriers to Using New Needles Questionnaire.  Findings. The median 
number of barriers reported was 5 (range 0-19).  Older age and longer injection history 
were significantly associated (p < 0.05) with reporting > 8 barriers. Fear of arrest by 
police (72% of PWIDs “agreed” or “strongly agreed”) and difficulty with purchasing 
needles from a pharmacy (64% “agreed” or “strongly agreed”) were the most frequently 
cited barriers. 
Conclusions.  Congruent with previous findings from urban heroin users, in rural West 
Virginia, the ability of people who inject drugs to use a clean needle obtained from a 
needle exchange for every injection may be compromised by fear of arrest.  In addition, 
pharmacy sales of clean needles to people who inject drugs may be blunted by an 
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absence of explicit laws mandating nonprescription sales.  Future studies should 
explore interventions that align the public health goals of needle exchange programs 
with the occupational safety of law enforcement and health outreach goals of 
pharmacists. 
Keywords:  needle exchange programs; hepatitis C virus; people who inject drugs; 
paraphernalia laws; barriers to using clean needles; policing behaviors 
INTRODUCTION 
The United States is currently in the midst of a hepatitis C virus (HCV) epidemic 
that has been catalyzed by injection drug use in rural areas.  Cases of acute HCV 
infection increased 98% between 2010 and 2015 with consistent annual increases 
observed during this time period (1).  Approximately 60 to 70% of HCV cases in the 
United States occur in people who inject drugs (PWID) (2, 3).  A disproportionate 
number of new HCV cases occur in young, white PWIDs residing in the rural, Central 
Appalachian region of the United States, which includes the states of Kentucky, 
Tennessee, Virginia, and West Virginia (1, 2, 4-6).  This region observed a 364% 
increase in new HCV cases between 2006 and 2012, (5) and three of the four states 
that comprise this region (West Virginia, Kentucky, and Tennessee) had the highest rate 
of new HCV infections in the United States (1).  This exponential increase in HCV cases 
has been associated with prescription opioid misuse that progresses to injection of 
heroin (7-10).   
Among PWIDs, the risk of HCV seroconversion increases 94% when syringes 
are shared during injection (11).  In an effort to minimize the reuse of needles, needle 
exchange programs (NEP) have been implemented as a mechanism for exchanging 
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used needles for clean (new) needles (9, 12).  Although the ability to access clean 
needles is one important step in fighting the HCV epidemic, there are potential barriers 
to practicing risk reduction strategies (e.g., not sharing syringes) that may reduce the 
efficacy of NEPs.  Barriers to using a clean needle for every injection can occur at the 
individual (e.g., being in drug withdrawal), interpersonal (e.g., peer influences), and 
societal (e.g., confiscation of needles by police) levels of influence (13), although there 
is a dearth of studies that empirically measure these barriers.  For example, after a 
thorough review of the extant literature, only one study was located.  In this study heroin 
injectors in Denver, Colorado in the United States were recruited and administered a 
structured interview that explored barriers associated with risk reduction practices (13). 
Being in drug withdrawal and fear of being arrested with needles were the two most 
frequently reported barriers to using new needles in this urban sample.  However, the 
barriers to using clean needles that may exist within the rural parts of the United States 
that are driving the recent HCV epidemic are currently unknown (14).  Therefore, the 
aim of this exploratory study was to identify self-reported barriers to using a clean 
needle among PWIDs attending NEPs in the state of West Virginia, which is located in 
the heart of Central Appalachia in the United States.  Improved understanding of these 
barriers may have implications for the efficacy of needle exchange for the prevention of 
HCV.  Based on the Denver study (13), we hypothesized that fear of arrest and drug 








We conducted a cross-sectional survey of PWIDs attending the first two NEPs to 
open in West Virginia, the Cabell-Huntington Health Department Syringe Exchange (15) 
and the Mylan Puskar Health Right LIGHT (Living in Good Health Together) Program 
(16). 
Measures 
We adapted the Barriers to Using New Needles Questionnaire (Cronbach’s alpha 
= 0.84) that was developed by Phillips et al. (13) and administered to a convenience 
sample of urban heroin users in Denver, Colorado to measure clean needle use barriers 
in our setting.  This questionnaire consists of 20 possible barriers to using a clean 
needle gleaned from clinical work and qualitative interviews.  Each participant indicates 
the extent to which s/he agrees with each item (barrier) according to a 5-point Likert 
scale ranging from “strongly disagree” to “strongly agree”.  
Prior to survey administration, we purposely selected and interviewed up to 5 
attendees at each NEP using methods similar to the technique of respondent 
debriefings (17).  Specifically, attendees were queried about survey comprehension and 
completeness (18).  Guiding questions were based on: 1) whether or not items were 
understandable; 2) whether or not response choices were adequate; 3) whether or not 
items were written in a manner that elicited only one response; and, 4) whether or not 
items were complete.  Item modifications were made as needed to maximize their 
applicability to the rural setting and avoid poorly defined words or terms that were not 
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universally understood (19).  To further enhance reliability and increase validity, the 
directors of both NEPs also reviewed these items.   
After item modifications, basic demographic questions querying age, gender, 
race/ethnicity, education level, employment status, housing status, HCV status, and 
injection history (e.g., frequency of injecting, years of injecting, etc.) were included in the 
final questionnaire (see Appendix).  To minimize potential bias stemming from 
participant and item nonresponse, the final survey was designed and pilot tested to take 
no more than 3-5 minutes to complete (18, 20).  Importantly, to minimize social 
desirability bias given the sensitive nature of the questions, the survey was anonymous 
(19).  
Participants and Procedure 
Based on consultation with the NEP program directors, a purposeful sample of 
100 attendees was planned.  This sample size was selected based on the following 
considerations: 1) Director´s assessment of maximum number of accessible 
participants; 2) the unstable and transient nature of the target population; and, 3) the 
minimum number needed to allow calculation of statistical differences in reported 
barriers by demographics and injection history.  To promote the number of responses, 
participants were personally invited by study staff to take the survey while attending the 
exchange (20).  The only requirements for participation were current exchange 
attendance and being at least 18 years of age. Participants were given a $10 gift card 
upon completion of the survey.  The West Virginia University Institutional Review Board 
approved the study and waived the requirement for written informed consent given that 
71 
 
the only document linking participants to the sensitive and potentially stigmatizing 
survey would be the consent form. 
Statistical analysis 
All survey data were entered into JMP® 13.0 Pro (21).  Item reliability was 
assessed using Cronbach’s   The median was imputed in cases where respondents 
gave a range of values instead of a single number (i.e., 5-10 injections = 7.5 injections; 
47% of cases) and in the 8% of cases with missing injection history.  Frequencies and 
descriptive statistics were calculated for all measured variables.  The extent to which 
demographic characteristics differed between respondents at each NEP was assessed 
using chi-square (or Fisher’s exact test when more than 20% of expected cell counts 
were < 5) for nominal or ordinal variables, and the t-test (or Wilcoxon test in the case of 
non-normally distributed outcomes) for continuous variables.  Normality of outcomes 
was assessed via the Shapiro-Wilk W test.  Continuous variables that significantly 
departed from normality were recoded into an ordinal variable based on distribution 
quartiles and a goal of creating category cell sizes that met the chi-square test 
requirement of no more than 20% of cells with expected counts < 5.  
Barriers to using clean needles 
The 5-point Likert response indicating agreement with each barrier was collapsed 
into a dichotomous “agree” (responses of “agree”, “strongly agree”) and “disagree” 
(responses of “strongly disagree”, “disagree”, “neutral”) variable for analysis to allow 
comparisons with a previous cohort of Denver heroin injectors that completed the 
Barriers to Using New Needles Questionnaire (13).  Contingency table analysis was 
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used to explore associations between nominal and ordinal demographic and injection 
history factors and 1) the number of barriers reported (<4, 4-8, > 8); and, 2) agreement 
with the individual barriers to clean needle use that were endorsed by more than 50% of 
respondents. Analysis of variance (ANOVA) was used to examine associations between 
age and reported barriers. An alpha of 0.05 was selected as the threshold for statistical 
significance.   
RESULTS 
Participants  
 To test the comprehension and completeness of the survey, two focus groups 
with 8 PWIDs (4 males, 4 females) drawn from attendees at both the Health Department 
NEP (n = 5) and the LIGHT Program (n = 3) were conducted.  All respondents felt that 
the Barriers to Using New Needles Questionnaire items were complete (i.e., no potential 
barriers were missed) and written in a manner that only elicited one response.  
Participants also felt that response choices (i.e., the 5-point Likert scale) were adequate 
and that most items were understandable with the exception of item 8 that discussed 
the potential barrier of using a new needle while injecting in a shooting gallery.  Several 
participants were unfamiliar with the term “shooting gallery”.  Therefore, we added a 
clarifying definition and a few terms (i.e., “dope den”, “joy popping”) taken directly from 
the transcripts of the focus groups that reflect the concept of a shooting gallery in our 




Overall, 100 PWIDs (Health Department, n = 74; LIGHT Program, n = 26) were 
approached and agreed to take the modified questionnaire (Cronbach’s  = 0.88).   
Respondents were generally young (i.e., < 40 yrs.; range = 18-63 yrs.) and Non-
Hispanic with slightly more males than females completing the survey.  Most 
respondents (78%) reported no education beyond high school, and 2/3rds (66%) were 
either unemployed or unable to work.  A substantial proportion of respondents (40%) 
reported that they were currently homeless and 1/3rd were HCV positive.  Respondents 
reported injecting between 1 and 18 times a day, 2 to 150 times a week, for 1 month to 
35 years.  There were no statistically significant differences between NEP sites in any of 
the demographic variables measured (see Table 1). 
Drug of choice 
Heroin was the most frequently cited drug of choice by respondents (n = 67, 
71.27%).  Other drugs of choice included methamphetamine (n = 16, 17.02%), 
buprenorphine (n = 11, 11.70%), cocaine (n = 2, 7.45%), fentanyl (n = 1, 2.13%), and 
amphetamines (n = 1, 1.06%).    
Barriers to using clean needles 
 Number of barriers reported 
 The median number of barriers to using clean needles among all participants 
was 5 (range 0-19).  PWIDs who reported > 8 barriers were significantly older than 
those reporting < 4 barriers (41.87 yrs. vs. 35.68 yrs., respectively; p = 0.02).  PWIDs 
who had been injecting for at least 8 years were significantly more likely to report > 8 
barriers to clean needle use compared to those injecting for < 3 years (41.67% versus 
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12.50%, respectively; p = 0.048).   There were no other significant differences (all p > 
0.05) in the number of barriers reported between sites, demographic categories, or by 
frequency of injection.   
 Barriers reported by more than half of respondents 
Among all 20 barriers, three items were endorsed by at least 50% of respondents 
(see Table 2).  Two of these barriers related to obtaining clean needles at pharmacies 
(items 11,13), and one reflected fear of arrest (item 20).   Fear of arrest was the most 
frequently cited barrier overall with 45% of respondents strongly agreeing and an 
additional 27% agreeing that it was a barrier to using clean needles.   Agreement with 
these three items did not differ significantly (all p > 0.05) by age, gender, race, ethnicity, 
education, employment status, housing status, HCV status, or injection history.  
DISCUSSION 
 We conducted the first study to empirically assess barriers to using clean 
needles by people who inject drugs and live in the Appalachian region of the United 
States that is currently in the midst of an opioid and hepatitis C epidemic.  As 
hypothesized, similar to urban, Denver, Colorado, fear of arrest by law enforcement 
officials was the most frequently reported barrier to using clean needles in our 
population.  However, we did not find being in withdrawal to be a significant barrier to 
clean needle use as we expected.  Rather, difficulty obtaining clean needles from 
pharmacies was the second most frequently cited barrier.  To our knowledge, this is the 
largest empirical study examining barriers to using clean needles as reported by the 
hard-to-reach PWID population currently attending a needle exchange program.  These 
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findings may have implications for the efficacy of needle exchange programs for the 
prevention of hepatitis C and other infectious diseases among PWIDs. 
 Previous studies examining barriers to practicing risk reduction strategies by 
PWIDs attending needle exchange programs have employed qualitative methods and 
focused on harm reduction strategies other than needle exchange (e.g., skin cleaning 
and test shots).  A seminal study by Williams (22) with 15 injection drug using women 
employed qualitative methods and examined barriers to “safe drug use”, but did not 
examine barriers to specific harm reduction strategies (i.e. using clean needles), 
although access to clean needles was cited as a barrier to safe drug use.  Latkin et al. 
(23) examined potential barriers to sharing needles before first cleaning them with 
bleach in 413 PWIDs residing in Baltimore, Maryland in the United States, and Gleghorn 
and Corby (24) conducted 17 focus groups in eight US cities with 154 PWIDs also 
looking at willingness to adopt guidelines for bleach disinfection of needles and 
syringes.  However, there is no evidence that cleaning needles with bleach is an 
effective strategy against the prevention of HCV in PWIDs (25), and the US Centers for 
Disease Control only recommends bleaching needles when clean, sterile needles are 
unavailable (26).  Therefore, in the present study, we were only interested in examining 
barriers to using a new needle.  In a more recent study, 90 PWIDs were recruited from 
three NEPs located in northeastern Ohio, Western Michigan, and southeastern 
Michigan in the United States, and participated in a structured interview that assessed 
barriers to conducting test shots and skin cleaning prior to injection (27).  Although 
using clean needles was the most frequently reported safe injection behavior in this 
cohort, barriers to using clean needles were not assessed.  
76 
 
Phillips (13) conducted a quantitative study examining barriers to using 
new/sterile needles with 48 heroin injectors in Denver, Colorado.  With the exception of 
geographical location, our sample of rural Appalachian injectors shared several 
characteristics with the recruited urban Denver heroin injectors.  Both samples were 
predominantly male (75% in Denver; 57% in Appalachia) and included only a small 
proportion of African-American injectors (4% in both studies).  Both samples had a 
predominantly high school education (11.65 years of education, on average, in Denver 
and 78% with a high school education or less in our study), and in both samples, 
approximately 4 in 10 individuals reported being homeless.  However, our sample had 
significantly more individuals identifying as Caucasian/White (96% versus 57%, 
respectively) and only one respondent identified as Hispanic.  Although heroin was the 
most frequently cited drug of choice in our study, we did have a few respondents list an 
alternative drug of choice, which is different from the study in Denver that exclusively 
enrolled heroin injectors.  
The overall number of barriers reported was slightly larger in the Denver sample 
compared to our study (average of 7.19 (SD, 3.62) barriers reported versus 6.02 (SD, 
4.61), respectively).  However, similar to our findings, only a small proportion of barriers 
was endorsed by at least 50% of respondents.  More specifically, only 5 of 20 barriers 
were endorsed by more than 50% of respondents in Denver, and only 3 of 20 barriers 
were endorsed by more than 50% in our rural setting, although an additional 2 barriers 
related to difficulties purchasing clean syringes at a pharmacy (items 15, 16) were 
endorsed by almost half of our sample.  
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Notably, and congruent with our findings, fear of arrest for possession of clean 
needles was the most frequently cited barrier in Denver (98% of injectors, 45 of 48).  
This finding is also congruent with other studies.  A recent qualitative case study of rural 
Appalachian NEPs by Davis et al. (14) observed a legal conundrum created by 
paraphernalia laws that manifested in PWIDs being cited for clean needle possessions. 
In a study examining self-reported reasons for needle sharing and not carrying bleach 
among PWIDs in Baltimore Maryland, 69% of participants reported knowing a fellow 
injector who had “gotten in trouble” by law enforcement for carrying needles (23).  
Furthermore, such fear of arrest may preclude exchange attendance to obtain clean 
needles.  An earlier study conducted with PWIDs attending NEPs in Rhode Island also 
observed fear of identification and/or police harassment as a significant barrier to 
exchange participation (28).  Consequently, the success of NEPs is directly contingent 
on close cooperation between law enforcement and public health officials.  In particular, 
Beletsky (29) noted a discrepancy between the “law on the books” (i.e., legality of 
syringe possession and exchange) and the “law on the streets” (i.e., discretionary 
behavior of law enforcement in the form of arrests and citations for needle 
possession)(29).  Therefore, a better understanding of law enforcement attitudes 
underlying variable enforcement behaviors is indicated.  Elucidation of these attitudes 
can form the basis of tailored interventions to promote law enforcement acceptance of 
NEPs at a local or regional level to improve success and acceptability (30).   
There is a dearth of literature regarding underlying police attitudes toward NEPs 
that may influence policing behaviors, particularly PWID arrests and syringe 
confiscations, that have been shown to increase the odds of receptive syringe sharing 
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(31).  A qualitative study of 14 police officers in Roade Island revealed negative 
attitudes toward syringe access programs primarily in the form of a belief that such 
programs enable injection drug use (29).  However, significant anxieties over 
transmission of disease (i.e., HIV, HCV) via needlestick injuries were also observed.  A 
more recent qualitative case study observed similar law enforcement anxieties over 
needlestick injuries, and suggested that NEP acceptance increased when police were 
educated on the prevention of blood borne viruses benefit of needle exchange and 
viewed these programs as a blood-borne intervention versus a drug intervention (14).  
Indeed, a seminal intervention with police officers in Rhode Island aimed at increasing 
understanding, awareness, and acceptance of syringe access programs suggested that 
occupational safety training could form the basis of a successful law enforcement 
intervention that aligns law enforcement with the public health goals of NEPs (30).   
Interestingly, the difficulties related to purchasing syringes at pharmacies 
observed in our study was not reported in the Denver sample.  According to a colleague 
from the School of Pharmacy, it is not illegal for pharmacists to sell syringes without a 
prescription in West Virginia.  However, these sales are left to the discretion of 
pharmacists who often have to weigh the public health goal of preventing infectious 
disease with concerns over endorsement of drug use, which may contribute to practice 
variability (Garofoli M, e-mail communication, 7 Nov, 2017).  Such variability has been 
documented in the United States with syringe purchase refusal rates between 23% and 
79% observed in states where nonprescription sale of syringes by pharmacies is legal 
(32-34).  Concerns over endorsement of drug use and stigmatization of drug users were 
among the factors associated with these refusals (32).  As a result of these findings, 
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there has been a call to pass legislation that explicitly mandates pharmacy sales of 
nonprescription syringes as opposed to current discretionary practices (32, 35).  
Education of pharmacists to promote awareness of existing state laws that allow 
nonprescription sales of clean needles and the efficacy of clean needle use in 
preventing infectious diseases has been advanced (32, 35).  Pharmacy policies that 
explicitly promote nonprescription syringe sales have been encouraged (36).  
Finally, we did not find being in withdrawal to be a barrier to using clean needles 
in our rural sample as was observed in Denver.  Whereas only one quarter of our 
respondents cited being in withdrawal as a barrier to using clean needles in our setting, 
65% either agreed or strongly agreed that this was a barrier in Denver, Colorado. 
Potential explanations for this discrepancy are unclear and warrants further 
investigation. 
Our findings are subject to some limitations.  The results may be subject to 
reporting bias, specifically in the form of social desirability bias.  However, we employed 
an anonymous survey design to minimize this source of bias.  Additionally, given the 
hard-to-reach PWID population, we were not able to employ a random sampling 
scheme, which may have biased our results.  Such bias could affect the generalizability 
of our findings both to other injectors attending the two NEP sites in our study and also 
to PWIDs attending other NEPs located within West Virginia (8 additional NEPs have 
opened in West Virginia (37) since the first two that were selected for this study).  
Furthermore, these results may not be applicable to PWIDs in other locales outside of 
the rural, Appalachian environment or even to other PWIDs in West Virginia.  These 
limitations notwithstanding, we were able to achieve a sample double the size of the 
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only other existing empirical study on potential barriers to using clean needles.  Future 
studies should seek to confirm these results in other locales and specifically examine 
the impact of paraphernalia laws and policing behaviors on the efficacy of the needle 
exchange model.   
CONCLUSIONS 
Fear of arrest for possessing clean needles and difficulties with pharmacy 
purchase of clean needles were the most commonly cited barriers to using new needles 
among our population of injection drug users attending two needle exchange programs 
in rural West Virginia.  Future studies should confirm these results in other rural settings 
and explore the design and implementation of individual and structural interventions 
with law enforcement officials and pharmacists that promote access to sterile syringes.   
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Demographics     
     
Age (avg.) 37.05 37.97 34.42 0.1307 
       
 % n % n %  
Gender       
Female 43 33 44.60 10 38.46  
Male 57 41 55.40 16 61.54 0.5869 
Education       
< High School 21 19 25.68 2 7.69  
High School Graduate 57 39 52.70 18 69.23  
>High School 22 16 21.62 6 23.08 0.1420 
Race       
White  96 71 95.95 25 96.15  
Black/African American 4 3 4.05 1 3.85 1.000 
Hispanic       
Yes 1 1 1.35 0 0  
No 98 72 97.30 26 100  
Missing 1 1 1.35 0 0 1.000 
Employment Status       
Employed 22 15 20.27 7 26.92  
Unemployed 42 30 40.54 12 46.15  
Unable to Work 24 20 27.03 4 15.39  
Other (e.g., Student) 12 9 12.16 3 11.54 0.6539 
Homeless       
Yes 40 33 44.60 7 26.92  
No 60 41 55.40 19 73.08 0.1136 
Hepatitis C Positive       
Yes 32 25 33.78 7 26.92  
No 58 41 55.41 17 65.39  
Don’t Know 10 8 10.81 2 7.69 0.6702 
     
Injection History     
Daily Injections (median) 5 5 5 0.6776 
Weekly Injections (median) 30 30 31.25 0.5678 
Duration Injecting (yrs.) 4 4 5.25 0.0612 
     
Barriers to Clean Needle Use     
# of Barriers (median) 5 5.5 5 0.7227 














Table 2.  Reported Barriers to Using New Needles by People Who Inject Drugs (N = 100) 
 
 
 Agree Disagree/Neutral 
 % % 
1. It takes too long to get a new needle every time I inject. 15 85 
2. It is inconvenient to get a new needle every time I inject. 24.74 75.26 
3. I often don’t want to take the time to get a new needle because my cravings or 
urges to use drugs are too strong.   
18.37 81.63 
4. I often do not take the time to get a new needle if I am drug sick or in withdrawal. 24.45 75.55 
5. I don’t take the time to get a new needle before injecting because I can only think 
about getting high. 
23.23 76.77 
6. I don’t take the time to get a new needle before injecting if I’m already high or 
drunk. 
19.39 80.61 
7. The places where I inject usually do not have access to new needles. 29.29 70.71 
8. If I am in a shooting gallery (a place where people inject drugs, “dope den”, “joy 
popping”, etc.), I often do not use a new needle. 
21.74 78.26 
9. I often do not carry new needles with me when I’m out. 30.93 69.07 
10. There isn’t a needle exchange close by for me to get needles. 16.67 83.33 
11. Pharmacies sometimes give me hassle when I try to buy needles. 63.33 36.37 
12. After I inject, I don’t prepare in advance by getting new needles ready for my next 
injection. 
39.80 60.20 
13. It’s too expensive to buy new needles from the pharmacy for every time I inject. 55.91 44.09 
14. Feeling sad or depressed would get in the way of my using a new needle every 
time I inject. 
20.21 79.79 
15. It is embarrassing to buy needles at the pharmacy. 47.92 52.08 
16. I worry that someone (friends, family, etc.) may see me buying needles at the 
pharmacy. 
49.47 50.53 
17. My peers/friends would look at me funny if I used a new needle every time I inject. 17.53 82.47 
18. Having to worry about using a new needle interrupts the ritual of using. 16.84 83.16 
19. I am unlikely to use a new needle if a friend lets me borrow his or her used needle. 19.59 80.41 











4 SUMMARY OF FINDINGS 
 
4.1 Study 1  
 
4.1.1  Findings 
An updated systematic review with meta-analysis (specific aim #1) yielded mixed 
results with regard to the efficacy of needle exchange programs for the prevention of 
hepatitis C in people who inject drugs.  Results from studies yielding odds ratio (OR) 
estimates indicated no effect on the odds of HCV seroconversion from NEP 
participation (OR, 0.51, 95% CI, 0.05–5.15); whereas, pooled results from studies 
yielding hazard ratio (HR) estimates indicated a harmful effect (HR, 2.05, 95% CI, 1.39–
3.03).53  
4.1.2 Discussion and Implications for Future Research 
The central finding of mixed evidence is likely due to substantial heterogeneity in 
study populations, interventions, comparisons, and outcomes.  In particular, there is 
some evidence that selecting HCV seroconversion as the primary outcome of interest 
may not be the outcome that best demonstrates the potentially protective effect of 
NEPs.  Rather, these programs have demonstrated substantially higher protective 
benefit in the form of a reduction in injection risk behavior (e.g., syringe sharing),17 
which is the number one risk factor for HCV seroconversion.14  Future systematic 
reviews and meta-analyses may, therefore, wish to focus on syringe sharing as the 
primary outcome of interest.  However, the aforementioned heterogeneity, especially in 
selected populations, specific intervention characteristics, and outcomes (and 
associated statistical analyses) may still preclude a pooling of meaningful results to 
86 
 
obtain estimates of overall effect. Therefore, there is a need for well-designed, 
standardized studies to clarify the overall efficacy of NEP on the prevention of HCV. 
With regard to the intervention itself, recent research suggests that the addition 
of opiate replacement therapy (ORT) that administers methadone or buprenorphine to 
needle exchange programs may more effectively prevent HCV seroconversion in 
PWIDs.  One meta-analysis demonstrated that such combined strategies reduced the 
risk of HCV seroconversion by 75% (pooled RR 0.25, 95% CI, 0.07-0.83) compared to 
effects from single method interventions that had relative risks (RRs) ranging from 0.6 to 
1.6.13  Similarly, a study pooling NEP plus ORT intervention results in the United 
Kingdom observed a 79% reduction in the odds of new HCV infection (aOR 0.21, 95% 
CI, 0.08-0.52),54 and another study from Scotland observed a 71% reduction (aOR 0.29, 
95% CI, 0.11-0.74) in new HCV cases.55  A very recent systematic review with meta-
analysis conducted by the Cochrane Collaboration found that combined ORT/NEP 
therapy was associated with a 76% reduction in HCV acquisition (RR = 0.24, 95% CI, 
0.07 – 0.89) versus NEP alone, which was associated with increased HCV risk in North 
American studies (RR = 1.58, P = <0.001).56  Interestingly and in contrast, high needle 
and syringe program coverage demonstrated a protective effect in Europe (RR=0.44, 
95% CI 0.24-0.80)56  However, identical to the findings of study #1, heterogeneity 
remained a significant problem in this meta-analysis, and the overall evidence was 
judged to be of low quality.  Furthermore, because all of the combined intervention 
studies included in these meta-analyses were conducted in Europe where methadone is 
frequently used as an ORT, there is no current information on whether or not differential 
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effects may exist for other opiate replacement therapies (i.e., buprenorphine) used in 
combination with NEP. 
It is plausible that observed reductions in the overall odds of HCV seroconversion 
from the combined approach may be due to demonstrated reductions in overall drug 
use and risky injection behavior, the latter of which is the chief risk factor for HCV 
seroconversion in PWIDs.14  For example, Turner et al.54 observed an average 
reduction of 20.8 injections per month and a 48% reduction (aOR 0.52, 95% CI, 0.32 – 
0.83) in the risk of needle sharing in PWIDs participating in full harm reduction (i.e., high 
NSP coverage and receiving ORT) in the United Kingdom.  Additionally, during a time of 
scaled-up coverage of combined harm reduction interventions in Scotland, the 
proportion of PWIDs injecting daily declined 14% (p < 0.001).55  However, more 
research is needed to clarify the overall impact of this combined strategy on prevention 
of HCV in PWIDs located in North America, where combined strategies are not widely 
available. Indeed, implementing combined NEP and ORT therapy may be challenged by 
the belief that opiate replacement therapy is intended to take an abstinence only 
approach (i.e., individuals on ORT should not be actively injecting drugs using needles 
obtained from a syringe access program).  For example, a pilot NEP implemented in 
Washington, DC shared office space with a methadone program, and some staff of the 
ORT program were strongly opposed to needle distribution in a treatment setting.57  
Therefore, any successful implementation of a combined strategy may require a 
substantial treatment paradigm shift.  To this end, future studies should seek to 
measure the attitudes and prevailing beliefs of ORT staff members located in the United 
States regarding a combined approach to combating the HCV epidemic.  Of note, and a 
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potential area for future research, is the fact that recent mathematical modeling 
suggests that a reduction in HCV prevalence will be greatest when direct-acting antiviral 
therapies such as sofosbuvir that can effectively cure HCV are combined with a scale 
up in coverage of both ORT and NEP interventions.58 
4.1.3  Strengths and Weaknesses 
 
This study was the first update to the only existing previous study13 specifically 
examining the efficacy of NEP for the prevention of HCV, and included studies with 
designs that promoted reaching causal conclusions (i.e., cohort or case-control 
designs).  However, the small number of studies that met our criteria precluded the 
assessment of small study effects (i.e., publication bias) and potential moderator 
effects.  As with any meta-analysis, the biases inherent in individual studies (e.g., 
information bias,59 volunteer bias60,61) will also be present in the pooled results, and 
aggregate results may not be applicable to individuals (i.e., the ecological fallacy62).    
This meta-analysis also excluded other sources of sterile needles such as 
supervised injection facilities (SIF) and pharmacies, which may increase the overall 
availability of clean needles available to PWIDs.63  However, as of 2017, SIFs were just 
opening in a few urban areas of the United States and none were present in the rural, 
Appalachian area that was the focus of this dissertation.  Similarly, there were no 
pharmacy-based NEPs operating in West Virginia at the time of this dissertation, and 
very limited evidence exists (N=2 studies)64 regarding the impact of pharmacy-based 
NEP on HCV prevention.  Therefore, future studies should explore the addition of other 
sources of clean needles on the prevention of HCV among PWIDs in rural Appalachia.  
Finally, and similar to previous research,13 this systematic review did not locate any 
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individual studies describing and examining the efficacy of NEP in rural areas.  This 
absence of information formed the rationale for study 2.   




A qualitative case study of two of the longest operating NEPs in the rural, 
Appalachian State of West Virginia (specific aim #2) revealed common barriers and 
facilitators to program implementation, ongoing operations, and future expansion.  
Although broad community support was a noted strength by both programs, ongoing 
operations were threatened by unexpected program demand and funding pressures 
created by the federal government’s ban on the use of funds to purchase needles. 
Structural barriers in the form of paraphernalia laws created a legal conundrum for 
attendees who reported criminal sanctions for the possession of needles, whether clean 
or used, which has been associated with increased syringe sharing.   
4.2.2 Discussion and Implications for Future Research 
 
The barriers and facilitators experienced by our small, rural Appalachian NEPs 
are similar to those reported by the first NEPs to open in the United States in urban 
areas such as Tacoma, Washington37,65; San Francisco, CA66; New York City67; and, 
Washington, DC.57  However, there is some evidence that NEPs located in rural areas 
may experience more funding pressures than other geographical regions.  A recent 
survey 68 revealed that rural NEPs more frequently reported funding difficulties in 
comparison to their urban and suburban counterparts. The specific factors related to 
this disparity are not well understood.  It is possible that these funding pressures are 
90 
 
merely reflective of the fact that rural areas of the United States are poorer than more 
urban areas.69  In comparison to the rest of the United States, the Appalachian region is 
economically disadvantaged with lower life expectancies and higher mortality, 70 and  
declining rural manufacturing and coal industry jobs have created areas that have been 
described as “chronically poor”.71  Other factors such as the overwhelming volume of 
attendees created by the opioid and heroin epidemics in Central Appalachia may also 
play a role in funding shortfalls.  Future studies examining factors driving this observed 
geographical funding disparity between urban, suburban and rural NEPs are indicated.  
The community support noted as a significant facilitator by both programs was 
somewhat unexpected and in contrast to historical controversy over needle exchange 
programs in the United States.72  Such controversy is rooted in the fact that drug use 
has historically been treated as a moral failing in need of a criminal solution in the 
United States.72  Increasing acceptance of the use of illicit substances such as 
marijuana73 may, in part, explain a shift in community attitudes towards needle 
exchange.  Even more conservative state and local governments have shown 
increasing support of NEPs in the face of infectious disease outbreaks of HIV and 
hepatitis C.74  Community support may also have been related to the spike in overdose 
deaths that precipitated the NEP implementation in one Appalachian community in this 
study.  Given the strong facilitative role of community support observed in this case 
study, future research should directly examine factors related to support of the NEP 
model in rural communities.  Increasing public support may translate into a change in 
federal policy to allow funds to be used for the purchase of sterile needles in addition to 
program operations.   
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The conundrum reported by several participants, including PWIDs and law 
enforcement members, over the action that should be taken upon discovery of needles, 
whether clean or used, is of particular concern given the relationship between criminal 
sanctions and the spread of infectious disease.  A study by Pollini et al.21 observed that 
arrests for needle possession were significantly associated with receptive syringe 
sharing, which is the number one risk factor for HCV seroconversion among PWIDs.14   
Pipitpan et al.20 also observed an association between syringe confiscation and lower 
safe injection self- efficacy (p = 0.04).   Whereas the action to be taken in the presence 
of clean needles is somewhat less clear, law enforcement members were unequivocal 
in their response to finding needles with drug residue (i.e., citation and/or arrest) in this 
qualitative case study.  This observation is of concern given that it threatens the entire 
exchange model.  If attendees fear potential arrest for possession of used needles, they 
may be less likely to bring used needles back to exchange for clean ones.  However, 
attendee fear of arrest and other potential barriers to using clean needles among 
PWIDs living in rural Appalachia had not previously been reported, and formed the 
primary basis for the third and final study of this dissertation.  
4.2.3 Strengths and Weaknesses 
 
This study is the first qualitative case study of rural needle exchange programs 
located in central Appalachia.  The implementation of qualitative research techniques 
yielded an in-depth understanding of barriers and facilitators to program 
implementation, ongoing operations, and future expansion from the viewpoints of 
program staff, law enforcement, and program attendees.  Findings from this study may 
inform the implementation and operation of exchanges in other central Appalachian 
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areas battling the current heroin epidemic in rural America.  However, some study 
limitations should be noted.  It is possible that responses may have been impacted by 
social desirability bias given the sensitive study topic.  To promote unbiased responses, 
no names or other demographic information were collected.  Given the convenience 
sample of respondents, it is also possible that the results observed in these two 
programs may not be transferable to other attendees within each program or other 
programs throughout the state.  Therefore, future studies should examine the 
congruency of our findings with other programs in West Virginia and other central 
Appalachian locales.  




Findings from a cross-sectional survey of PWIDs attending two needle 
exchanges in West Virginia (specific aim #3) suggest that there are significant structural 
barriers to the efficacy of NEPs.  In specific, paraphernalia laws and concomitant 
policing behaviors (i.e., needle confiscation and/or arrest) may contribute to the inability 
of PWIDs to both bring used needles back for exchange and have clean needles 
available for use during every injection.  Attendees also reported difficulties with 
purchasing needles at pharmacies without a prescription, which may be related to an 
absence of explicit state laws permitting such sales. 
4.3.2 Discussion and Implications for Future Research 
 
The central finding of fear of law enforcement sanctions (e.g., arrest, syringe 
confiscation, etc.) as a primary barrier to using a clean needle for every injection may 
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threaten the efficacy of the needle exchange model in preventing infectious diseases 
(e.g., HCV) and is congruent with interview data gathered during the second aim of this 
dissertation. This central barrier may be driven by 1) confusion over existing 
paraphernalia laws; and, 2) law enforcement attitudes and experiences. 
Paraphernalia laws that differ by state and locations within each state in the 
United States may create confusion among both PWIDs and law enforcement regarding 
the legality of syringe possession, whether clean or used.  For example, in the United 
States, 28 states have either limited or removed previous laws prohibiting needle 
distribution, 17 have explicitly authorized NEPs, and 14 states have removed syringes 
from the definition of drug paraphernalia.75  Within this tangled web of legislation, over 
200 NEPs are currently known to operate.75  Therefore, it is not surprising that law 
enforcement unawareness of laws that allow purchase and possession of needles in 
some locations have been documented.76,77  Additionally, existing studies examining 
police attitudes toward needle exchange programs highlight the difficulty reported by 
officers that are sworn to uphold the law (confusion and lack of awareness 
notwithstanding), on the one hand, with a program that some view as explicitly 
encouraging illegal behavior, on the other hand.76-79    
There is some initial evidence76 that educational interventions combining 
occupational safety training with an understanding of the public health benefits of 
needle exchange may promote a better understanding of paraphernalia laws that allow 
possession of clean needles and more positive attitudes toward harm reduction 
programs among law enforcement officers.  A preliminary, 30-minute in-service training 
with Rhode Island police officers combined public health content (i.e., the harm 
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reduction model) with occupational safety information (i.e., needlestick risks), and 
observed positive posttest shifts in legal and occupational safety knowledge.76  After 
training, officers correctly understood that it was legal for PWIDs to possess clean 
syringes in their setting (OR = 9.16, 95% CI, 4.80–17.51).76  Participants were also 
significantly more likely to understand the low risk of HIV transmission in the event of a 
needlestick injury (OR = 3.22, 95% CI, 1.78–523).  However, attitudes about harm 
reduction programs, were only slightly altered and observed increases were not 
statistically significant.  Post-training, a 2% increase in the odds of believing that harm 
reduction programs do not promote drug use was observed (OR = 1.02, 95% CI, 0.59–
1.76).76  Similarly, post intervention, a 17% increase in the odds of believing that harm 
reduction programs reduce the risk of needlestick injuries was observed (OR = 1.17, 
95% CI, 0.68–2.03).76  The authors suggest that long-standing, entrenched cultural 
beliefs may necessitate the need for law enforcement champions to facilitate changing 
underlying attitudes.76  This suggestion is congruent with study 2 of this dissertation, 
which observed the significant facilitative role that law enforcement champions played in 
the implementation and ongoing operations of NEPs in two rural, Appalachian 
communities.  Notably, these champions promoted the intervention as a blood-borne 
intervention versus a drug intervention and emphasized the importance linkage to drug 
cessation services.  Therefore, it may be necessary to increase awareness among law 
enforcement officers that harm reduction programs provide linkage to care with the goal 
of ultimately serving as a gateway to recovery.  However, further research is needed on 
the long-term effects of such educational interventions on the actual behaviors of law 
enforcement toward PWIDs found with either used or clean needles.   
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A more recent study suggests that policing behaviors may be associated with 
actual experiences.  Cepeda et al.78 surveyed over 1300 officers in Tijuana, Mexico and 
observed 38% higher odds of syringe confiscation among officers reporting needlestick 
injuries (OR 1.38, 95% CI, 1.02–1.87).  Based on these results, the authors suggest that 
negative attitudes toward PWIDs stemming from previous needlestick injuries may lead 
to more syringe confiscations.78   Therefore, interventions that seek to reduce the odds 
of experiencing a needlestick injury, which is at the core of the occupational safety 
component of the previous intervention with Rhode Island officers, may reduce syringe 
confiscation behaviors, and is an area in need of further research.  However, findings 
from this study also suggested that policing behaviors may be positively associated with 
underlying attitudes.  Although not statistically significant, the odds of arresting a PWID 
were 22% less among officers who held a positive view of laws that treat addiction as a 
public health issue (aOR = 0.78, 95% CI, 0.59–1.03).78  Therefore, the public health 
component of the intervention conducted with Rhode Island law enforcement may also 
translate to policing behaviors that promote non-confiscation of needles, and is another 
area in need of further inquiry.  Ultimately, the most successful interventions may 
balance increasing positive attitudes and decreasing negative occupational 
experiences.  For example, police concerns over acquiring infectious diseases, 
especially HCV, via a needlestick injury have been shown to increase stress, lead to an 
exaggeration of actual seroconversion risk, and result in a hostile attitude toward PWIDs 
that may promote policing behaviors that decrease the effectiveness of harm reduction 
programs.80  However, the success of any intervention is moot in the absence of laws 
that decriminalize possession of both clean and used needles.  One strategy 
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implemented by a NEP in Study 2 was the use of biohazard containers for needle 
transportation.  It is unclear whether this strategy could minimize the confiscation and/or 
legal sanctioning of PWIDs found with needles, and is an area ripe for further inquiry.   
As it currently stands, fear of arrest may blunt the effectiveness of needle exchange in 
our rural Appalachian program.  The presence of these structural influences on the 
performance of the exchange model could possibly explain, in part, the discrepancy 
between European NEPs that have been shown to be protective against the acquisition 
of hepatitis C versus North American NEPs that have been shown to increase the risk of 
HCV as discussed above.  
The trouble experienced by PWIDs with obtaining nonprescription syringes from 
pharmacies, although not directly impacting needle exchange programs, may have 
implications for the future role of pharmacies in serving as an additional source of sterile 
needles.  Lack of explicit direction from both state policies and professional 
organizations creates a professional conundrum whereby pharmacists must weigh the 
public health benefit of nonprescription syringe sales with concerns over explicit 
encouragement of illegal activity.81,82  In some cases pharmacists may be unaware of 
the legality of nonprescription sales.83,84 In others, pharmacists have expressed concern 
over the impact that PWIDs purchasing syringes in stores may have on staff safety and 
other customers.83  Such concerns have led some pharmacists to support NEPs in their 
neighborhood while continuing to oppose nonprescription pharmacy sales of 
syringes.82,85 Therefore, interventions only targeting pharmacists’ knowledge of the 
legality of nonprescription syringe sales may not necessarily result in increasing sales.83  
There have also been calls for professional pharmaceutical organizations to explicitly 
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endorse the nonprescription sales of sterile syringes,84 and explicit state laws 
mandating such sales may promote access to clean syringes.83   
4.3.3 Strengths and Weaknesses 
 
This study used a psychometrically validated survey and obtained a sample size 
double the only other existing published study19 surveying PWIDs attending a needle 
exchange program on potential barriers to using a clean needle for every injection.  
However, social desirability bias is a noted limitation of our findings given the sensitivity 
of the survey questions.  To minimize this bias, we made the survey entirely 
anonymous. Given the hard-to-reach PWID population, we were also only able to obtain 
a convenience sample of attendees.  This sampling scheme may limit the 
generalizability of our findings to both attendees at the two sites surveyed in West 
Virginia and to attendees in other rural locations.  Future studies should seek to confirm 
these results in other locales and specifically examine the impact of paraphernalia laws 
and policing behaviors on the efficacy of the needle exchange model.     
5   CONCLUSION 
People who inject drugs living in rural communities, particularly those located in 
the Central Appalachian region of the United States, continued to be a primary driver of 
the overall Hepatitis C Virus epidemic in the United States.  However, these 
communities lag far behind their suburban and urban counterparts with regard to the 
availability of needle exchange programs.68  The results of this dissertation suggest that 
NEPs opened in rural Central Appalachia in response to an opioid and heroin epidemic 
have enjoyed robust community support and are viewed as an important infectious 
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diseases prevention mechanism by people who inject drugs in the rural Appalachian 
communities examined.  However, the overall impact of NEPs on preventing HCV in 
rural injection drug users is unclear and, similar to urban areas of the United States, 
may be blunted by legal structural influences (i.e. paraphernalia laws) that impact 
policing behaviors.  Future studies should explore the factors associated with these 
structural barriers that may prevent the ability of rural PWIDs to use a clean needle 
during every injection, which, in turn, may minimize the overall efficacy of these 
programs on HCV prevention.  Further research is also needed on the feasibility of 
implementing the addition of opiate replacement therapy with needle exchange 
programs given the strong protective effect on HCV acquisition among PWIDs observed 
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drug addict 
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7.1.4 CINHAL Search Details 
 
CINHAL Search 7/18/16 
 
S1 (hepatitis C OR HCV) AND 
(intravenous drug abuse OR 
intravenous drug use OR drug 
misuse OR drug addict OR 
injecting drug use OR drug 
abuse OR people who inject 
drugs OR IDU OR PWID) AND 
(prevention OR risk factor OR 
epidemiology OR prevalence 
OR incidence OR 
seroprevalence OR 
seroincidence OR 
seroconversion OR genotype 
OR coinfect*) AND (needle 
exchange OR needle 
exchange program OR syringe 
exchange program OR syringe 
access program)  
Search modes - Find all my search terms 
 




7.2 Study 2 Interview Guides 
 




“Thank you again for taking the time to discuss your exchange program today. Over the next hour I will be asking you a series of questions 
about the past, present, and future of your program. Everything we discuss will remain confidential, and I will not identify your program by 
name in any publications that may result from this qualitative research study. As a reminder, participation in this study is entirely voluntary 
and you can choose to stop at any time without penalty.  This research study is being completed as part of a dissertation for a Doctorate in 
Public Health degree, and has been reviewed and acknowledged by the WVU Institutional Review Board.” 
 
“Would you like to begin the interview?” 
 
If NO: “I understand. Thank you again for letting me visit today. Have a nice day.” 
 
If YES: “Great! To help me remember everything we discuss, I would like to audio record our interview, which will be transcribed and 
analyzed. Would it be okay if I audio recorded our interview today?” 
 
IF NO: “I understand. Would it be okay if I wrote some notes during our interview?” 
 
IF YES: “Great! Let’s get started. I’m going to turn the audio recorder on now.” [Turn on audio recorder] 
 
Timeframe Guiding Questions 
Past 1. Can you tell me a little bit about how the program started? [Probe for precipitating events]  
2. Can you tell me about some of the major facilitators that helped make the program possible? [Probe for 
champions] 
3. Can you tell me about some of the major barriers encountered to opening the program? [Probe for 
local/state/legal] 
Present 4.  “When did the program open?”  
5. “In our email exchange, you mentioned you adapted the policies from New York’s model…can you talk 
a little bit about the specific changes/adaptations and why those changes were made?” “ 
6. Can you tell me a little bit about the organizational structure of the program?” [Probe for number of 
staff members] 
7. “Can you tell me a little bit about how the program is funded?” [Probe for budget figures/expenditure 
items (staff, needles, other supplies)/funding challenges/cost-effectiveness] 
8. “Can you tell me a little bit about how the program operates?” [Probe for program location 
(ideal?)/program hours/days per week/other services provided in addition to needle exchange] 
9. “Can you tell me a little bit about the program’s attendees?” [Probe for number of 
attendees/demographics/attendance trends/number HCV positive/number on opiate substitution 
therapy/identification and/or registration requirements/number needles exchanged]  
10. “Can you tell me a little bit about any current difficulties related to program operations?” [Probe for 
drug paraphernalia walls/political environment/opponents] 
11. “Can you tell me a little bit about the things that are helpful to program operations?”  For example, 
what is something that you don’t think the program could function optimally without?” 
12. “What are the surrounding community’s feelings about the program?” [Probe for relationship with 
media] 
13. Can you tell me about the program’s relationship with the local health department? 
 
Future 14.  What, if anything, would you change about the current program? 
15. Dream big! What is your goal for this program in 1 year? 5 years? [Probe for barriers to realizing 
future goals] 
 
“Thank you sincerely for your time today. Once the data are analyzed, I would like to speak with you again regarding the results to get your 
thoughts. Have a nice day.” 
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7.2.2 Law Enforcement  
 
Introductory Script 
“Thank you again for taking the time to discuss your thoughts on the local exchange program today. Over the next hour I will be asking you a series 
of questions about the past, present, and future of the program. Everything we discuss will remain confidential, and I will not identify you by name 
in any publications that may result from this qualitative research study. As a reminder, participation in this study is entirely voluntary and you can 
choose to stop at any time without penalty.  This research study is being completed as part of a dissertation for a Doctorate in Public Health 
degree, and has been reviewed and acknowledged by the WVU Institutional Review Board.” 
 
“Would you like to begin the interview?” 
 
If NO: “I understand. Thank you again for letting me visit today. Have a nice day.” 
 
If YES: “Great! To help me remember everything we discuss, I would like to audio record our interview, which will be transcribed and analyzed. 
Would it be okay if I audio recorded our interview today?” 
 
IF NO: “I understand. Would it be okay if I wrote some notes during our interview?” 
 
IF YES: “Great! Let’s get started. I’m going to turn the audio recorder on now.” [Turn on audio recorder] 
 
Timeframe Guiding Questions 
Past 16. Can you tell me a little bit about how the program started? [Probe for precipitating events]  
17. Can you tell me about some of the major facilitators that helped make the program possible? [Probe for 
champions] 
18. Can you tell me about some of the major barriers encountered to opening the program? [Probe for 
local/state/legal] 
Present 19. “How would you characterize the program’s current relationship with the police department?” 
20.   “Can you tell me a little bit about the impact of the program on law enforcement? [Probe for dirty    
needles/confiscation of clean needles/perceived impact on drug use/perceived impact on drug related 
problems/crime]  
21. “Can you discuss the ways in which the program has impacted your daily job?” 
22. Can you tell me a little bit more about your feelings regarding the program’s location [Probe for proximity to 
the police station] 
23. “Can you tell me a little bit about the program’s attendees?”  
24. “Can you tell me a little bit about any current difficulties related to the program?” [Probe for drug 
paraphernalia laws/political environment/opponents/naloxone availability/overdose concerns] 
25. “Can you tell me a little bit about the things that are helpful to the program?”  For example, what is 
something that you don’t think the program could function optimally without?” 
26. “What are the surrounding community’s feelings about the program?”  
Future 27.  What, if anything, would you change about the current program? 










“Thank you again for taking the time to discuss your experiences with the exchange program and your opinions on clean syringe use today. My 
name is Steve Davis, and I am with the WVU Department of Emergency Medicine.  This research study is being completed as part of a dissertation 
for a Doctorate in Public Health degree, and has been reviewed and acknowledged by the WVU Institutional Review Board.  If you have any 
questions about this research, you can contact me at 304 – 293 – 1326 or via my email at smdavis@hsc.wvu.edu. ” 
 
Over the next 30 minutes I will be asking you a series of questions about your experiences with the exchange and your opinions about an 
anonymous survey on barriers to using clean syringes (or needles).   We plan to administer this survey to fellow attendees in the near future. Your 
responses will help us understand if the survey makes sense and if we have potentially left out any important barriers to clean syringe use.  
Everything we discuss will remain confidential, and I will not identify you by name in any publications or reports that may result from this research 
study.  As a reminder, participation in this study is entirely voluntary and you can choose to skip any question and stop at any time without penalty.   
 
“Would you like to begin the interview?” 
 
If NO: “I understand. Thank you again for letting me visit today. Have a nice day.” 
 
If YES: “Great! To help me remember everything we discuss, I would like to audio record our interview, which will be transcribed and analyzed. 
Would it be okay if I audio recorded our interview today?” 
 
IF NO: “I understand. Would it be okay if I wrote some notes during our interview?” 
 
IF YES: “Great! Please do not give your name or any other identifying information during our discussions, and please do not share anything we 
discuss today outside of this interview.  Also, please do not record your individual responses to the Barriers to Using New Needles survey. Let’s get 
started. I’m going to turn the audio recorder on now.” [Turn on audio recorder] 
 
PART 1 (TRIANGULATION) Guiding Questions 
 29. What do you call this place?  
30. Can you tell me a little bit about what it was like for attendees before the exchange opened? 
{PAST} 
31. Can you tell me a little bit more about the current need for the program? [probe for increasing 
volumes or volume changes/infectious disease prevention/linkage to treatment] {PRESENT} 
32. Can you tell me a little bit about any current difficulties related to using the exchange?” [probe 
for transportation barriers, location barriers, legal barriers (i.e., fear of arrest), community 
opposition, wait times that may be related to increasing volumes)] {PRESENT} 
33. Can you tell me a little bit about the things that are helpful to operating the program?”  For 
example, what is something that you don’t think the program could function optimally 
without?”  [probe for community/people champions/funding] {PRESENT} 
34. Dream big! What changes would you like to see in the program in 1 year? 5 years? [probe for 





PART 2 (SURVEY 
COMPREHENSION) 
Guiding Questions 
Give participants the 
Barriers to Using New 
Needles survey and have 
them complete the 
questionnaire but NOT 
record their actual results. 
 




Once finished, ask the guide 
questions  
1. Understandable:  Were the items “understandable”? That is, were you able to read the 
questions once and understand what it was they were asking? Were the meanings of the 
questions clear and straightforward?  
2. Adequate: Were the answer choices (i.e., “strongly agree”, “strongly disagree”) “adequate”? 
That is, do you feel the choices provided you with an appropriate way to respond?   
3. Only One Response: Were the items written in such a way that you could have answered in 
only one way (i.e., you did not wish to answer BOTH “strongly agree” and “strongly disagree”).   
4. Complete:  Were there any other barriers to using a clean syringe that you feel were not 
included in the items? If so, what are they? 
 
 
“Thank you sincerely for your time today. Once the data are analyzed, I would like to speak with you again regarding the results to get your 
thoughts. Have a nice day.” 
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7.3 Study 3 Barriers to Using New Needles Survey 
Part I.  For each question, please circle only one (1) response.   
 1 2 3 4 5  
1. It takes too long to get a new needle every time I inject. Strongly 
Disagree 





2. It is inconvenient to get a new needle every time I inject. Strongly 
Disagree 





3. I often don’t want to take the time to get a new needle because my cravings or urges to 
use drugs are too strong.   
Strongly 





4. I often do not take the time to get a new needle if I am drug sick or in withdrawal. Strongly 
Disagree 





5. I don’t take the time to get a new needle before injecting because I can only think about 
getting high. 
Strongly 





6. I don’t take the time to get a new needle before injecting if I’m already high or drunk. Strongly 
Disagree 





7. The places where I inject usually do not have access to new needles. Strongly 
Disagree 





8. If I am in a shooting gallery (a place where people inject drugs, “dope den”, “joy 
popping”, etc.), I often do not use a new needle. 
Strongly 





9. I often do not carry new needles with me when I’m out. Strongly 
Disagree 





10. There isn’t a needle exchange close by for me to get needles. Strongly 
Disagree 





11. Pharmacies sometimes give me hassle when I try to buy needles. Strongly 
Disagree 





12. After I inject, I don’t prepare in advance by getting new needles ready for my next 
injection. 
Strongly 





13. It’s too expensive to buy new needles from the pharmacy for every time I inject. Strongly 
Disagree 





14. Feeling sad or depressed would get in the way of my using a new needle every time I 
inject. 
Strongly 





15. It is embarrassing to buy needles at the pharmacy. Strongly 
Disagree 





16. I worry that someone (friends, family, etc.) may see me buying needles at the pharmacy. Strongly 
Disagree 





17. My peers/friends would look at me funny if I used a new needle every time I inject. Strongly 
Disagree 





18. Having to worry about using a new needle interrupts the ritual of using. Strongly 
Disagree 





19. I am unlikely to use a new needle if a friend lets me borrow his or her used needle. Strongly 
Disagree 





20. I could get in trouble from the police if I carry needles around with me. Strongly 
Disagree 





PLEASE FLIP OVER AND COMPLETE PART II    
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PART II.  For the following questions, please answer or check () the appropriate response. 
  
21.  What is your age? (in years) _____ 26.  What is your current employment status (check only one)?*  
  
22.   What is your sex?  Employed for wages 
  Self-employed 
 Female  Out of work for more than 1 year 
 Male  Out of work for less than 1 year 
  A Homemaker 
23.  What is the highest grade or year of school you completed?*  A Student 
  Retired 
 Never attended school or only attended kindergarten  Unable to work 
 Elementary  
 Some high school 27.  Are you currently homeless? 
 High School graduate (or GED)  
 Some college or technical school  Yes 
 College graduate  No 
 Some graduate or professional school  
 Graduate or professional degree (for example, MS, PhD, MD) 28.  How many times do you usually inject each day?  
       ____  (number of injections) 
  
24.  How would you describe your race? (Check all that apply)* 29.  How many times do you usually inject each week?   
       ____  (number of injections) 
  
 White  30.  How long have you been injecting? ______years  
 Black or African American                         OR (if less than 1 year) ______months 
 Asian  
 Native Hawaiian or Pacific Islander   31.  What is your drug of choice (i.e., what drug do you most often  
 American Indian or Alaska Native inject)? ___________________________________________ 
 Other:________________________________________  
 32.  Are you hepatitis C positive? 
      25. Are you Hispanic or Latino (if female, Latina)?*  
  Yes 
 Yes  No 
 No  Don’t Know 
THANK YOU! PLEASE RETURN THE COMPLETED 
SURVEY TO MR. DAVIS AND RECEIVE YOUR $10 
SHEETZ GIFT CARD TODAY.    
 
* Adapted from:  CDC. 2014 Behavioral Risk Factor Surveillance System 
Questionnaire. 2013; https://www.cdc.gov/brfss/questionnaires/pdf-
ques/2014_BRFSS.pdf. Accessed March 5th, 2015. 
 
